{"id":"regadenoson","rwe":[],"_fda":{"id":"4b43c865-fcdb-4e57-30a4-871e37e0e593","set_id":"03ef6420-8190-a404-f7f6-def1864a77de","openfda":{"nui":["N0000193963","N0000175788"],"unii":["7AXV542LZ4"],"route":["INTRAVENOUS"],"spl_id":["4b43c865-fcdb-4e57-30a4-871e37e0e593"],"brand_name":["Regadenoson"],"spl_set_id":["03ef6420-8190-a404-f7f6-def1864a77de"],"package_ndc":["43598-616-11"],"product_ndc":["43598-616"],"generic_name":["REGADENOSON"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["REGADENOSON ANHYDROUS"],"pharm_class_epc":["Pharmacologic Cardiac Stress Test Agent [EPC]"],"pharm_class_moa":["Adenosine Receptor Agonists [MoA]"],"manufacturer_name":["Dr. Reddy's Laboratories Inc."],"application_number":["ANDA213210"],"is_original_packager":[true]},"version":"3","pregnancy":["8.1 Pregnancy Risk Summary There are no available data on regadenoson use in pregnant women to inform a drug-associated risk. In animal reproduction studies, adverse developmental outcomes were observed with the administration of regadenoson to pregnant rats and rabbits during organogenesis only at doses that produced maternal toxicity (see Data). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Reproductive studies in rats showed that regadenoson doses 10 and 20 times the maximum recommended human dose (MRHD) based on body surface area caused reduced fetal body weights and significant ossification delays in fore- and hind limb phalanges and metatarsals; maternal toxicity also occurred at these doses. Skeletal variations were increased in all treated groups. In rabbits, maternal toxicity occurred at regadenoson doses administered during organogenesis at 4 times the MRHD; however, there were no teratogenic effects in offspring at this dose. At higher doses, 12 and 20 times the MRHD, maternal toxicity occurred along with increased embryo-fetal loss and fetal malformations."],"overdosage":["10 OVERDOSAGE Regadenoson overdosage may result in serious reactions [see Warnings and Precautions ( 5 )]. In a study of healthy volunteers, symptoms of flushing, dizziness and increased heart rate were assessed as intolerable at regadenoson doses greater than 0.02 mg/kg. Aminophylline to Reverse Effects Methylxanthines, such as caffeine, aminophylline, and theophylline, are competitive adenosine receptor antagonists and aminophylline has been used to terminate persistent pharmacodynamic effects. Aminophylline may be administered in doses ranging from 50 mg to 250 mg by slow intravenous injection (50 mg to 100 mg over 30–60 seconds). Methylxanthine use is not recommended in patients who experience a seizure in association with regadenoson administration [see Warnings and Precautions ( 5.8) ]."],"description":["11 DESCRIPTION Regadenoson is an A 2A adenosine receptor agonist that is a coronary vasodilator [see Clinical Pharmacology ( 12.1 ) ]. Regadenoson is chemically described as adenosine, 2-[4-[(methylamino)carbonyl]-1 H -pyrazol-1-yl].Its structural formula is: The molecular formula for regadenoson is C 15 H 18 N 8 O 5 and its molecular weight is 390.35. Regadenoson is a sterile, nonpyrogenic solution for intravenous injection. The solution is clear and colorless. Each 1 mL in the 5 mL pre-filled syringe contains 0.08 mg regadenoson on an anhydrous basis, 10.9 mg dibasic sodium phosphate dihydrate, 5.4 mg monobasic sodium phosphate monohydrate, 150 mg propylene glycol, 1 mg edetate disodium dihydrate, and Water for Injection, with pH between 6.3 and 7.7."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Regadenoson injection is supplied as a sterile, preservative-free clear colorless solution containing 0.08 mg/mL regadenoson in the following package: Single-dose 5 mL pre-filled plastic syringes with luer-lock fitting (NDC 43598-616-11). Store at 20° to 25°C (68° to 77°F); [See USP Controlled Room Temperature]."],"geriatric_use":["8.5 Geriatric Use Of the 1,337 patients receiving regadenoson in Studies 1 and 2, 56% were 65 years of age and over and 24% were 75 years of age and over. Older patients (≥ 75 years of age) had a similar adverse event profile compared to younger patients (< 65 years of age), but had a higher incidence of hypotension (2% vs. ≤ 1%)."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20221101","clinical_studies":["14 CLINICAL STUDIES Agreement between REGADENOSON and ADENOSCAN The efficacy and safety of regadenoson were determined relative to ADENOSCAN in two randomized, double-blind studies (Studies 1 and 2) in 2,015 patients with known or suspected coronary artery disease who were indicated for pharmacologic stress MPI. A total of 1,871 of these patients had images considered valid for the primary efficacy evaluation, including 1,294 (69%) men and 577 (31%) women with a median age of 66 years (range 26–93 years of age). Each patient received an initial stress scan using ADENOSCAN (6-minute infusion using a dose of 0.14 mg/kg/min, without exercise) with a radionuclide gated SPECT imaging protocol. After the initial scan, patients were randomized to either regadenoson or ADENOSCAN, and received a second stress scan with the same radionuclide imaging protocol as that used for the initial scan. The median time between scans was 7 days (range of 1–104 days). The most common cardiovascular histories included hypertension (81%), CABG, PTCA or stenting (51%), angina (63%), and history of myocardial infarction (41%) or arrhythmia (33%); other medical history included diabetes (32%) and COPD (5%). Patients with a recent history of serious uncontrolled ventricular arrhythmia, myocardial infarction, or unstable angina, a history of greater than first-degree AV block, or with symptomatic bradycardia, sick sinus syndrome, or a heart transplant were excluded. A number of patients took cardioactive medications on the day of the scan, including β-blockers (18%), calcium channel blockers (9%), and nitrates (6%). In the pooled study population, 68% of patients had 0–1 segments showing reversible defects on the initial scan, 24% had 2–4 segments, and 9% had ≥ 5 segments. Comparison of the images obtained with regadenoson to those obtained with ADENOSCAN was performed as follows. Using the 17-segment model, the number of segments showing a reversible perfusion defect was calculated for the initial ADENOSCAN study and for the randomized study obtained using regadenoson or ADENOSCAN. The agreement rate for the image obtained with regadenoson or ADENOSCAN relative to the initial ADENOSCAN image was calculated by determining how frequently the patients assigned to each initial ADENOSCAN category (0–1, 2–4, 5–17 reversible segments) were placed in the same category with the randomized scan. The agreement rates for regadenoson and ADENOSCAN were calculated as the average of the agreement rates across the three categories determined by the initial scan. Studies 1 and 2 each demonstrated that regadenoson is similar to ADENOSCAN in assessing the extent of reversible perfusion abnormalities (Table 7). Table 7 Agreement Rates in Studies 1 and 2 Study 1 Study 2 ADENOSCAN – ADENOSCAN Agreement Rate (± SE) 61 ± 3% 64 ± 4% ADENOSCAN – Regadenoson Agreement Rate (± SE) 62 ± 2% 63 ± 3% Rate Difference (Regadenoson– ADENOSCAN) (± SE) 95% Confidence Interval 1 ± 4% -7.5, 9.2% -1 ± 5% -11.2, 8.7% Use of Regadenoson in Patients with Inadequate Exercise Stress The efficacy and safety of regadenoson administered 3 minutes (Group 1) or 1 hour (Group 2) following inadequate exercise stress were evaluated in an open-label randomized, multi-center, non-inferiority study. Adequate exercise was defined as ≥ 85% maximum predicted heart rate and ≥ 5 METS. SPECT MPI was performed 60-90 minutes after regadenoson administration in each group (MPI 1). Patients returned 1-14 days later to undergo a second stress MPI with regadenoson without exercise (MPI 2). All patients were referred for evaluation of coronary artery disease. Of the 1,147 patients randomized, a total of 1,073 patients received regadenoson and had interpretable SPECT scans at all visits; 538 in Group 1 and 535 in Group 2. The median age of the patients was 62 years (range 28 to 90 years) and included 633 (59%) men and 440 (41%) women. Images from MPI 1 and MPI 2 for the two groups were compared for presence or absence of perfusion defects. The level of agreement between the MPI 1 and the MPI 2 reads in Group 1 was similar to the level of agreement between MPI 1 and MPI 2 reads in Group 2. However, two patients receiving regadenoson 3 minutes following inadequate exercise experienced a serious cardiac adverse reaction. No serious cardiac adverse reactions occurred in patients receiving regadenoson 1 hour following inadequate exercise stress [see Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.2) ]."],"pharmacodynamics":["12.2 Pharmacodynamics Coronary Blood Flow Regadenoson causes a rapid increase in CBF which is sustained for a short duration. In patients undergoing coronary catheterization, pulsed-wave Doppler ultrasonography was used to measure the average peak velocity (APV) of coronary blood flow before and up to 30 minutes after administration of regadenoson (0.4 mg, intravenously). Mean APV increased to greater than twice baseline by 30 seconds and decreased to less than twice the baseline level within 10 minutes [see Clinical Pharmacology ( 12 .3) ]. Myocardial uptake of the radiopharmaceutical is proportional to CBF. Because regadenoson increases blood flow in normal coronary arteries with little or no increase in stenotic arteries, regadenoson causes relatively less uptake of the radiopharmaceutical in vascular territories supplied by stenotic arteries. MPI intensity after regadenoson administration is therefore greater in areas perfused by normal relative to stenosed arteries. Effect of duration of injection A study in dogs compared the effects of intravenous injection of 2.5 µg/kg regadenoson (in 10 mL) over 10 seconds and 30 seconds on CBF. The duration of a two-fold increase in CBF was 97±14 seconds (n=6) and 221±20 seconds (n=4), respectively, for the 10 second and 30 second injections. The peak effects (i.e., maximal increase) on CBF after the 10 second and 30 second injections were 217±15% and 297±33% above baseline, respectively. The times to peak effect on CBF were 17±2 seconds and 27±6 seconds, respectively. Effect of Aminophylline Aminophylline (100 mg, administered by slow intravenous injection over 60 seconds) injected 1 minute after 0.4 mg regadenoson in patients undergoing cardiac catheterization, was shown to shorten the duration of the coronary blood flow response to regadenoson as measured by pulsed- wave Doppler ultrasonography [see Overdosage ( 10) ]. Effect of Caffeine Ingestion of caffeine decreases the ability to detect reversible ischemic defects. In a placebo- controlled, parallel group clinical study, patients with known or suspected myocardial ischemia received a baseline rest/stress MPI followed by a second stress MPI. Patients received caffeine or placebo 90 minutes before the second regadenoson stress MPI. Following caffeine administration (200 or 400 mg), the mean number of reversible defects identified was reduced by approximately 60%. This decrease was statistically significant [see Drug Interactions ( 7.1) and Patient Counseling Information ( 17) ]. Hemodynamic Effects In clinical studies, the majority of patients had an increase in heart rate and a decrease in blood pressure within 45 minutes after administration of regadenoson. Maximum hemodynamic changes after regadenoson and ADENOSCAN in Studies 1 and 2 are summarized in Table 5. Table 5 Hemodynamic Effects in Studies 1 and 2 Vital Sign Parameter REGADENOSON N = 1,337 ADENOSCAN N = 678 Heart Rate > 100 bpm 22% 13% Increase > 40 bpm 5% 3% Systolic Blood Pressure < 90 mm Hg 2% 3% Decrease > 35 mm Hg 7% 8% ≥ 200 mm Hg 1.9% 1.9% Increase ≥ 50 mm Hg 0.7% 0.8% ≥ 180 mm Hg and increase of ≥ 20 mm Hg from baseline 4.6% 3.2% Diastolic Blood Pressure < 50 mm Hg 2% 4% Decrease > 25 mm Hg 4% 5% ≥ 115 mm Hg 0.9% 0.9% Increase ≥ 30 mm Hg 0.5% 1.1% Hemodynamic Effects Following Inadequate Exercise In a clinical study, regadenoson was administered for MPI following inadequate exercise stress. More patients with regadenoson administration three minutes following inadequate exercise stress had an increase in heart rate and a decrease in systolic blood pressure compared with regadenoson administered at rest. The changes were not associated with any clinically significant adverse reactions. Maximum hemodynamic changes are presented in Table 6. Table 6 Hemodynamic Effects in Inadequate Exercise Stress Study Vital Sign Parameter Group 1 / MPI 1 Regadenoson 3 minutes following exercise (N=575) Group 2 / MPI 1 Regadenoson 1 hour following exercise (N=567) Heart Rate > 100 bpm 44% 31% Increase > 40 bpm 5% 16% Systolic Blood Pressure < 90 mm Hg 2% 4% Decrease > 35 mm Hg 29% 10% ≥ 200 mm Hg 0.9% 0.4% Increase ≥ 50 mm Hg 2% 0.4% ≥ 180 mm Hg and increase of ≥ 20 mm Hg from baseline 5% 2% Diastolic Blood Pressure < 50 mm Hg 3% 3% Decrease > 25 mm Hg 6% 5% ≥ 115 mm Hg 0.7% 0.4% Increase ≥ 30 mm Hg 2% 1% Respiratory Effects The A 2B and A 3 adenosine receptors have been implicated in the pathophysiology of bronchoconstriction in susceptible individuals (i.e., asthmatics). In in vitro studies, regadenoson has not been shown to have appreciable binding affinity for the A 2B and A 3 adenosine receptors. In a randomized, placebo-controlled clinical trial of 999 patients with a diagnosis, or risk factors for, coronary artery disease and concurrent asthma or COPD, the incidence of respiratory adverse reactions (dyspnea, wheezing) was greater with regadenoson compared to placebo. Moderate (2.5%) or severe (< 1%) respiratory reactions were observed more frequently in the regadenoson group compared to placebo [see Adverse Reactions ( 6.1 ) ]."],"pharmacokinetics":["12.3 Pharmacokinetics In healthy subjects, the regadenoson plasma concentration-time profile is multi-exponential in nature and best characterized by 3-compartment model. The maximal plasma concentration of regadenoson is achieved within 1 to 4 minutes after injection of regadenoson and parallels the onset of the pharmacodynamic response. The half-life of this initial phase is approximately 2 to 4 minutes. An intermediate phase follows, with a half-life on average of 30 minutes coinciding with loss of the pharmacodynamic effect. The terminal phase consists of a decline in plasma concentration with a half-life of approximately 2 hours [see Clinical Pharmacology ( 12.2) ]. Within the dose range of 0.3–20 µg/kg in healthy subjects, clearance, terminal half-life or volume of distribution do not appear dependent upon the dose. A population pharmacokinetic analysis including data from subjects and patients demonstrated that regadenoson clearance decreases in parallel with a reduction in creatinine clearance and clearance increases with increased body weight. Age, gender, and race have minimal effects on the pharmacokinetics of regadenoson. Specific Populations Renally Impaired Patients: The disposition of regadenoson was studied in 18 patients with various degrees of renal function and in 6 healthy subjects. With increasing renal impairment, from mild (CLcr 50 to < 80 mL/min) to moderate (CLcr 30 to < 50 mL/min) to severe renal impairment (CLcr < 30 mL/min), the fraction of regadenoson excreted unchanged in urine and the renal clearance decreased, resulting in increased elimination half-lives and AUC values compared to healthy subjects (CLcr ≥ 80 mL/min). However, the maximum observed plasma concentrations as well as volumes of distribution estimates were similar across the groups. The plasma concentration- time profiles were not significantly altered in the early stages after dosing when most pharmacologic effects are observed. No dose adjustment is needed in patients with renal impairment. Patients with End Stage Renal Disease: The pharmacokinetics of regadenoson in patients on dialysis has not been assessed; however, in an in vitro study regadenoson was found to be dialyzable. Hepatically Impaired Patients : The influence of hepatic impairment on the pharmacokinetics of regadenoson has not been evaluated. Because greater than 55% of the dose is excreted in the urine as unchanged drug and factors that decrease clearance do not affect the plasma concentration in the early stages after dosing when clinically meaningful pharmacologic effects are observed, no dose adjustment is needed in patients with hepatic impairment. Geriatric Patients: Based on a population pharmacokinetic analysis, age has a minor influence on the pharmacokinetics of regadenoson. No dose adjustment is needed in elderly patients. Metabolism The metabolism of regadenoson is unknown in humans. Incubation with rat, dog, and human liver microsomes as well as human hepatocytes produced no detectable metabolites of regadenoson. Excretion In healthy volunteers, 57% of the regadenoson dose is excreted unchanged in the urine (range 19- 77%), with an average plasma renal clearance around 450 mL/min, i.e., in excess of the glomerular filtration rate. This indicates that renal tubular secretion plays a role in regadenoson elimination."],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the labeling. Myocardial Ischemia [see Warnings and Precautions ( 5.1 ) ] Sinoatrial and Atrioventricular Nodal Block [see Warnings and Precautions ( 5.2 ) ] Atrial Fibrillation/Atrial Flutter [see Warnings and Precautions ( 5.3 ) ] Hypersensitivity, Including Anaphylaxis [see Warnings and Precautions ( 5.4 ) ] Hypotension [see Warnings and Precautions ( 5.5 ) ] Hypertension [see Warnings and Precautions ( 5.6 ) ] Bronchoconstriction [see Warnings and Precautions ( 5.7 ) ] Seizure [see Warnings and Precautions ( 5.8 ) ] Cerebrovascular Accident (Stroke) [see Warnings and Precautions ( 5.9 ) ] The most common (incidence ≥ 5%) adverse reactions to regadenoson injection are dyspnea, headache, flushing, chest discomfort, dizziness, angina pectoris, chest pain, and nausea ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy's Laboratories Inc., at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. During clinical development, 1,651 patients were exposed to regadenoson, with most receiving 0.4 mg as a rapid (≤ 10 seconds) intravenous injection. Most of these patients received regadenoson in two clinical studies that enrolled patients who had no history of bronchospastic lung disease as well as no history of a cardiac conduction block of greater than first-degree AV block, except for patients with functioning artificial pacemakers. In these studies (Studies 1 and 2), 2,015 patients underwent myocardial perfusion imaging after administration of regadenoson (N = 1,337) or ADENOSCAN (N = 678). The population was 26–93 years of age (median 66 years), 70% male and primarily Caucasian (76% Caucasian, 7% African American, 9% Hispanic, 5% Asian). Table 1 shows the most frequently reported adverse reactions. Overall, any adverse reaction occurred at similar rates between the study groups (80% for the regadenoson group and 83% for the ADENOSCAN group). Aminophylline was used to treat the reactions in 3% of patients in the regadenoson group and 2% of patients in the ADENOSCAN group. Most adverse reactions began soon after dosing, and generally resolved within approximately 15 minutes, except for headache which resolved in most patients within 30 minutes. Table 1 Adverse Reactions in Studies 1 and 2 Pooled (Frequency ≥ 5%) REGADENOSON N = 1,337 ADENOSCAN N = 678 Dyspnea 28% 26% Headache 26% 17% Flushing 16% 25% Chest Discomfort 13% 18% Angina Pectoris or ST Segment Depression 12% 18% Dizziness 8% 7% Chest Pain 7% 10% Nausea 6% 6% Abdominal Discomfort 5% 2% Dysgeusia 5% 7% Feeling Hot 5% 8% ECG Abnormalities The frequency of rhythm or conduction abnormalities following regadenoson or ADENOSCAN is shown in Table 2 [see Warnings and Precautions ( 5.2 )]. Table 2 Rhythm or Conduction Abnormalities* in Studies 1 and 2 REGADENOSON N / N evaluable (%) ADENOSCAN N / N evaluable (%) Rhythm or conduction abnormalities† 332/1275 (26%) 192/645 (30%) Rhythm abnormalities 260/1275 (20%) 131/645 (20%) PACs 86/1274 (7%) 57/645 (9%) PVCs 179/1274 (14%) 79/645 (12%) First-degree AV block (PR prolongation > 220 msec) 34/1209 (3%) 43/618 (7%) Second-degree AV block 1/1209 (0.1%) 9/618 (1%) AV conduction abnormalities (other than AV blocks) 1/1209 (0.1%) 0/618 (0%) Ventricular conduction abnormalities 64/1152 (6%) 31/581 (5%) *12-lead ECGs were recorded before and for up to 2 hours after dosing. †includes rhythm abnormalities (PACs, PVCs, atrial fibrillation/flutter, wandering atrial pacemaker, supraventricular or ventricular arrhythmia) or conduction abnormalities, including AV block. Respiratory Abnormalities In a randomized, placebo-controlled trial of 999 patients with asthma (n = 532) or stable chronic obstructive pulmonary disease (n = 467), the overall incidence of pre-specified respiratory adverse reactions was greater in the regadenoson group compared to the placebo group (p < 0.001). Most respiratory adverse reactions resolved without therapy; a few patients received aminophylline or a short-acting bronchodilator. No differences were observed between treatment arms in the reduction of >15% from baseline at two-hours in FEV 1 (Table 3). Table 3 Respiratory Adverse Effects * Asthma Cohort Chronic Obstructive Pulmonary Disease (COPD) Cohort Regadenoson (N=356) Placebo (N=176) Regadenoson (N=316) Placebo (N=151) Overall Pre-specified Respiratory Adverse Reaction † 12.9% 2.3% 19.0% 4.0% Dyspnea 10.7% 1.1% 18.0% 2.6% Wheezing 3.1% 1.1% 0.9% 0.7% FEV 1 reduction >15% ‡ 1.1% 2.9% 4.2% 5.4% *All patients continued the use of their respiratory medications as prescribed prior to administration of regadenoson. †Patients may have reported more than one type of adverse reaction. Adverse reactions were collected up to 24 hours following drug administration. Pre-specified respiratory adverse reactions included dyspnea, wheezing, obstructive airway disorder, dyspnea exertional, and tachypnea. ‡Change from baseline at 2 hours. Renal Impairment In a randomized, placebo-controlled trial of 504 patients (regadenoson n=334 and placebo n=170) with a diagnosis or risk factors for coronary artery disease and NKFK/DOQI Stage III or IV renal impairment (defined as GFR 15-59 mL/min/1.73 m 2 ), no serious adverse events were reported through the 24-hour follow-up period. Inadequate Exercise Stress In an open-label, multi-center trial evaluating regadenoson administration following inadequate exercise stress, 1,147 patients were randomized into one of two groups. Each group underwent two regadenoson stress myocardial perfusion imaging (MPI) procedures. Group 1 received regadenoson 3 minutes following inadequate exercise in the first regadenoson stress (MPI 1). Group 2 rested 1 hour after inadequate exercise to allow hemodynamics to return to baseline prior to receiving regadenoson (MPI 1). Both groups returned for a second stress MPI 1-14 days later and received regadenoson without exercise (MPI 2). The most common adverse reactions are similar in type and incidence to those in Table 1 above for both Groups. The timing of the administration of regadenoson following inadequate exercise did not alter the common adverse reaction profile. Table 4 shows a comparison of cardiac events of interest for the two groups [see Warnings and Precautions ( 5.1 ) ]. The cardiac events were numerically higher in Group 1. Table 4 Cardiac Events of Interest in Inadequate Exercise Stress Study Cardiac Event* Group 1 / MPI 1 Regadenoson 3 minutes following exercise (N=575) Group 2 / MPI 1 Regadenoson 1 hour following exercise (N=567) 17 (3.0%) 3 (0.5%) Holter/12-Lead ECG Abnormality ST-T Depression (≥ 2 mm) 13 (2.3%) 2 (0.4%) ST-T Elevation (≥ 1 mm) 3 (0.5%) 1 (0.2%) Acute coronary syndrome 1 (0.2%) 0 Myocardial infarction 1 (0.2%) 0 *A clinically significant cardiac event was defined as any of the following events found on the Holter ECG/12-lead ECG within one hour after regadenoson administration: ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, Torsade de Pointes, ventricular flutter); ST-T depression (≥ 2 mm); ST-T elevation (≥ 1 mm); AV block (2:1 AV block, AV Mobitz I, AV Mobitz II, complete heart block); sinus arrest > 3 seconds in duration Or a Treatment Emergent Adverse Event (TEAE) per the MedDRA SMQ (narrow Scope) for myocardial infarction Or a TEAE preferred term (PT) of angina unstable within 24 hours of regadenoson administration. 6.2 Post-Marketing Experience The following adverse reactions have been reported from worldwide marketing experience with regadenoson. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiovascular Myocardial infarction, cardiac arrest, ventricular arrhythmias, supraventricular tachyarrhythmias including atrial fibrillation with rapid ventricular response (new-onset or recurrent), atrial flutter, heart block (including third-degree block), asystole, marked hypertension, symptomatic hypotension in association with transient ischemic attack, acute coronary syndrome (ACS), seizures and syncope [see Warnings and Precautions ( 5.1 ), ( 5.2 ) , ( 5.3 ) , ( 5.5 ) , ( 5.6 ) and ( 5.8 ) ] have been reported. Some events required intervention with fluids and/or aminophylline [see Overdosage ( 10 ) ]. QTc prolongation shortly after regadenoson administration has been reported. Central Nervous System Tremor, seizure, transient ischemic attack, and cerebrovascular accident including intracranial hemorrhage [see Warnings and Precautions ( 5.8) and ( 5.9) ]. Gastrointestinal Abdominal pain, occasionally severe, has been reported a few minutes after regadenoson administration, in association with nausea, vomiting, or myalgias; administration of aminophylline, an adenosine antagonist, appeared to lessen the pain. Diarrhea and fecal incontinence have also been reported following regadenoson administration. Hypersensitivity Anaphylaxis, angioedema, cardiac or respiratory arrest, respiratory distress, decreased oxygen saturation, hypotension, throat tightness, urticaria, rashes have occurred and have required treatment including resuscitation [see Warnings and Precautions ( 5.4 ) ]. Musculoskeletal Musculoskeletal pain has occurred, typically 10-20 minutes after regadenoson administration; the pain was occasionally severe, localized in the arms and lower back and extended to the buttocks and lower legs bilaterally. Administration of aminophylline appeared to lessen the pain. Respiratory Respiratory arrest, dyspnea and wheezing have been reported following regadenoson administration.","6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. During clinical development, 1,651 patients were exposed to regadenoson, with most receiving 0.4 mg as a rapid (≤ 10 seconds) intravenous injection. Most of these patients received regadenoson in two clinical studies that enrolled patients who had no history of bronchospastic lung disease as well as no history of a cardiac conduction block of greater than first-degree AV block, except for patients with functioning artificial pacemakers. In these studies (Studies 1 and 2), 2,015 patients underwent myocardial perfusion imaging after administration of regadenoson (N = 1,337) or ADENOSCAN (N = 678). The population was 26–93 years of age (median 66 years), 70% male and primarily Caucasian (76% Caucasian, 7% African American, 9% Hispanic, 5% Asian). Table 1 shows the most frequently reported adverse reactions. Overall, any adverse reaction occurred at similar rates between the study groups (80% for the regadenoson group and 83% for the ADENOSCAN group). Aminophylline was used to treat the reactions in 3% of patients in the regadenoson group and 2% of patients in the ADENOSCAN group. Most adverse reactions began soon after dosing, and generally resolved within approximately 15 minutes, except for headache which resolved in most patients within 30 minutes. Table 1 Adverse Reactions in Studies 1 and 2 Pooled (Frequency ≥ 5%) REGADENOSON N = 1,337 ADENOSCAN N = 678 Dyspnea 28% 26% Headache 26% 17% Flushing 16% 25% Chest Discomfort 13% 18% Angina Pectoris or ST Segment Depression 12% 18% Dizziness 8% 7% Chest Pain 7% 10% Nausea 6% 6% Abdominal Discomfort 5% 2% Dysgeusia 5% 7% Feeling Hot 5% 8% ECG Abnormalities The frequency of rhythm or conduction abnormalities following regadenoson or ADENOSCAN is shown in Table 2 [see Warnings and Precautions ( 5.2 )]. Table 2 Rhythm or Conduction Abnormalities* in Studies 1 and 2 REGADENOSON N / N evaluable (%) ADENOSCAN N / N evaluable (%) Rhythm or conduction abnormalities† 332/1275 (26%) 192/645 (30%) Rhythm abnormalities 260/1275 (20%) 131/645 (20%) PACs 86/1274 (7%) 57/645 (9%) PVCs 179/1274 (14%) 79/645 (12%) First-degree AV block (PR prolongation > 220 msec) 34/1209 (3%) 43/618 (7%) Second-degree AV block 1/1209 (0.1%) 9/618 (1%) AV conduction abnormalities (other than AV blocks) 1/1209 (0.1%) 0/618 (0%) Ventricular conduction abnormalities 64/1152 (6%) 31/581 (5%) *12-lead ECGs were recorded before and for up to 2 hours after dosing. †includes rhythm abnormalities (PACs, PVCs, atrial fibrillation/flutter, wandering atrial pacemaker, supraventricular or ventricular arrhythmia) or conduction abnormalities, including AV block. Respiratory Abnormalities In a randomized, placebo-controlled trial of 999 patients with asthma (n = 532) or stable chronic obstructive pulmonary disease (n = 467), the overall incidence of pre-specified respiratory adverse reactions was greater in the regadenoson group compared to the placebo group (p < 0.001). Most respiratory adverse reactions resolved without therapy; a few patients received aminophylline or a short-acting bronchodilator. No differences were observed between treatment arms in the reduction of >15% from baseline at two-hours in FEV 1 (Table 3). Table 3 Respiratory Adverse Effects * Asthma Cohort Chronic Obstructive Pulmonary Disease (COPD) Cohort Regadenoson (N=356) Placebo (N=176) Regadenoson (N=316) Placebo (N=151) Overall Pre-specified Respiratory Adverse Reaction † 12.9% 2.3% 19.0% 4.0% Dyspnea 10.7% 1.1% 18.0% 2.6% Wheezing 3.1% 1.1% 0.9% 0.7% FEV 1 reduction >15% ‡ 1.1% 2.9% 4.2% 5.4% *All patients continued the use of their respiratory medications as prescribed prior to administration of regadenoson. †Patients may have reported more than one type of adverse reaction. Adverse reactions were collected up to 24 hours following drug administration. Pre-specified respiratory adverse reactions included dyspnea, wheezing, obstructive airway disorder, dyspnea exertional, and tachypnea. ‡Change from baseline at 2 hours. Renal Impairment In a randomized, placebo-controlled trial of 504 patients (regadenoson n=334 and placebo n=170) with a diagnosis or risk factors for coronary artery disease and NKFK/DOQI Stage III or IV renal impairment (defined as GFR 15-59 mL/min/1.73 m 2 ), no serious adverse events were reported through the 24-hour follow-up period. Inadequate Exercise Stress In an open-label, multi-center trial evaluating regadenoson administration following inadequate exercise stress, 1,147 patients were randomized into one of two groups. Each group underwent two regadenoson stress myocardial perfusion imaging (MPI) procedures. Group 1 received regadenoson 3 minutes following inadequate exercise in the first regadenoson stress (MPI 1). Group 2 rested 1 hour after inadequate exercise to allow hemodynamics to return to baseline prior to receiving regadenoson (MPI 1). Both groups returned for a second stress MPI 1-14 days later and received regadenoson without exercise (MPI 2). The most common adverse reactions are similar in type and incidence to those in Table 1 above for both Groups. The timing of the administration of regadenoson following inadequate exercise did not alter the common adverse reaction profile. Table 4 shows a comparison of cardiac events of interest for the two groups [see Warnings and Precautions ( 5.1 ) ]. The cardiac events were numerically higher in Group 1. Table 4 Cardiac Events of Interest in Inadequate Exercise Stress Study Cardiac Event* Group 1 / MPI 1 Regadenoson 3 minutes following exercise (N=575) Group 2 / MPI 1 Regadenoson 1 hour following exercise (N=567) 17 (3.0%) 3 (0.5%) Holter/12-Lead ECG Abnormality ST-T Depression (≥ 2 mm) 13 (2.3%) 2 (0.4%) ST-T Elevation (≥ 1 mm) 3 (0.5%) 1 (0.2%) Acute coronary syndrome 1 (0.2%) 0 Myocardial infarction 1 (0.2%) 0 *A clinically significant cardiac event was defined as any of the following events found on the Holter ECG/12-lead ECG within one hour after regadenoson administration: ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, Torsade de Pointes, ventricular flutter); ST-T depression (≥ 2 mm); ST-T elevation (≥ 1 mm); AV block (2:1 AV block, AV Mobitz I, AV Mobitz II, complete heart block); sinus arrest > 3 seconds in duration Or a Treatment Emergent Adverse Event (TEAE) per the MedDRA SMQ (narrow Scope) for myocardial infarction Or a TEAE preferred term (PT) of angina unstable within 24 hours of regadenoson administration.","6.2 Post-Marketing Experience The following adverse reactions have been reported from worldwide marketing experience with regadenoson. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiovascular Myocardial infarction, cardiac arrest, ventricular arrhythmias, supraventricular tachyarrhythmias including atrial fibrillation with rapid ventricular response (new-onset or recurrent), atrial flutter, heart block (including third-degree block), asystole, marked hypertension, symptomatic hypotension in association with transient ischemic attack, acute coronary syndrome (ACS), seizures and syncope [see Warnings and Precautions ( 5.1 ), ( 5.2 ) , ( 5.3 ) , ( 5.5 ) , ( 5.6 ) and ( 5.8 ) ] have been reported. Some events required intervention with fluids and/or aminophylline [see Overdosage ( 10 ) ]. QTc prolongation shortly after regadenoson administration has been reported. Central Nervous System Tremor, seizure, transient ischemic attack, and cerebrovascular accident including intracranial hemorrhage [see Warnings and Precautions ( 5.8) and ( 5.9) ]. Gastrointestinal Abdominal pain, occasionally severe, has been reported a few minutes after regadenoson administration, in association with nausea, vomiting, or myalgias; administration of aminophylline, an adenosine antagonist, appeared to lessen the pain. Diarrhea and fecal incontinence have also been reported following regadenoson administration. Hypersensitivity Anaphylaxis, angioedema, cardiac or respiratory arrest, respiratory distress, decreased oxygen saturation, hypotension, throat tightness, urticaria, rashes have occurred and have required treatment including resuscitation [see Warnings and Precautions ( 5.4 ) ]. Musculoskeletal Musculoskeletal pain has occurred, typically 10-20 minutes after regadenoson administration; the pain was occasionally severe, localized in the arms and lower back and extended to the buttocks and lower legs bilaterally. Administration of aminophylline appeared to lessen the pain. Respiratory Respiratory arrest, dyspnea and wheezing have been reported following regadenoson administration."],"contraindications":["4 CONTRAINDICATIONS Do not administer regadenoson injection to patients with: Second- or third-degree AV block, or sinus node dysfunction unless these patients have a functioning artificial pacemaker [see Warnings and Precautions ( 5.2) ]. Do not administer regadenoson injection to patients with: · Second- or third-degree AV block, or · sinus node dysfunction unless the patients have a functioning artificial pacemaker (4) ."],"drug_interactions":["7 DRUG INTERACTIONS No formal pharmacokinetic drug interacion studies have been conducted with regadenoson. Methylxanthines, e.g., caffeine, aminophylline and theophylline, interfere with the activity of regadenoson injection (7.1, 12.2 ). Aminophylline may be used to attenuate severe and/or persistent adverse reactions to regadenoson injection (7.1, 10) . Dipyridamole may increase the activity of regadenoson injection. When possible, withhold dipyridamole for at least two days prior to regadenoson injection administration (7.1) . 7.1 Effects of Other Drugs on Regadenoson • Methylxanthines (e.g., caffeine, aminophylline and theophylline) are non-specific adenosine receptor antagonists that interfere with the vasodilation activity of regadenoson [see Clinical Pharmacology ( 12.2) and Patient Counseling Information ( 17) ]. Patients should avoid consumption of any products containing methylxanthines as well as any drugs containing theophylline or aminophylline for at least 12 hours before regadenoson administration. Aminophylline may be used to attenuate severe or persistent adverse reactions to regadenoson [see Overdosage ( 10 ) ]. • In clinical studies, regadenoson was administered to patients taking other cardioactive drugs (i.e., β- blockers, calcium channel blockers, ACE inhibitors, nitrates, cardiac glycosides, and angiotensin receptor blockers) without reported adverse reactions or apparent effects on efficacy. • Dipyridamole may change the effects of regadenoson. When possible, withhold dipyridamole for at least two days prior to regadenoson administration. 7.2 Effect of Regadenoson on Other Drugs Regadenoson does not inhibit the metabolism of substrates for CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 in human liver microsomes, indicating that it is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 enzymes.","7.1 Effects of Other Drugs on Regadenoson • Methylxanthines (e.g., caffeine, aminophylline and theophylline) are non-specific adenosine receptor antagonists that interfere with the vasodilation activity of regadenoson [see Clinical Pharmacology ( 12.2) and Patient Counseling Information ( 17) ]. Patients should avoid consumption of any products containing methylxanthines as well as any drugs containing theophylline or aminophylline for at least 12 hours before regadenoson administration. Aminophylline may be used to attenuate severe or persistent adverse reactions to regadenoson [see Overdosage ( 10 ) ]. • In clinical studies, regadenoson was administered to patients taking other cardioactive drugs (i.e., β- blockers, calcium channel blockers, ACE inhibitors, nitrates, cardiac glycosides, and angiotensin receptor blockers) without reported adverse reactions or apparent effects on efficacy. • Dipyridamole may change the effects of regadenoson. When possible, withhold dipyridamole for at least two days prior to regadenoson administration.","7.2 Effect of Regadenoson on Other Drugs Regadenoson does not inhibit the metabolism of substrates for CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 in human liver microsomes, indicating that it is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 enzymes."],"labor_and_delivery":["8.2 Lactation Risk Summary There is no information on the presence of regadenoson in human milk, the effects on the breastfed infant, or the effects on milk production. Because of the potential risk of serious cardiac reactions in the breastfed infant, advise the nursing mother to pump and discard breast milk for 10 hours after administration of regadenoson."],"mechanism_of_action":["12.1 Mechanism of Action Regadenoson is a low affinity agonist (K i ≈ 1.3 µM) for the A 2A adenosine receptor, with at least 10-fold lower affinity for the A 1 adenosine receptor (K i > 16.5 µM), and weak, if any, affinity for the A 2B and A 3 adenosine receptors. Activation of the A 2A adenosine receptor by regadenoson produces coronary vasodilation and increases coronary blood flow (CBF)."],"recent_major_changes":["Dosage and Administration (2) 5/2018 Warnings and Precautions, Myocardial Ischemia (5.1) 5/2018"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Regadenoson is a low affinity agonist (K i ≈ 1.3 µM) for the A 2A adenosine receptor, with at least 10-fold lower affinity for the A 1 adenosine receptor (K i > 16.5 µM), and weak, if any, affinity for the A 2B and A 3 adenosine receptors. Activation of the A 2A adenosine receptor by regadenoson produces coronary vasodilation and increases coronary blood flow (CBF). 12.2 Pharmacodynamics Coronary Blood Flow Regadenoson causes a rapid increase in CBF which is sustained for a short duration. In patients undergoing coronary catheterization, pulsed-wave Doppler ultrasonography was used to measure the average peak velocity (APV) of coronary blood flow before and up to 30 minutes after administration of regadenoson (0.4 mg, intravenously). Mean APV increased to greater than twice baseline by 30 seconds and decreased to less than twice the baseline level within 10 minutes [see Clinical Pharmacology ( 12 .3) ]. Myocardial uptake of the radiopharmaceutical is proportional to CBF. Because regadenoson increases blood flow in normal coronary arteries with little or no increase in stenotic arteries, regadenoson causes relatively less uptake of the radiopharmaceutical in vascular territories supplied by stenotic arteries. MPI intensity after regadenoson administration is therefore greater in areas perfused by normal relative to stenosed arteries. Effect of duration of injection A study in dogs compared the effects of intravenous injection of 2.5 µg/kg regadenoson (in 10 mL) over 10 seconds and 30 seconds on CBF. The duration of a two-fold increase in CBF was 97±14 seconds (n=6) and 221±20 seconds (n=4), respectively, for the 10 second and 30 second injections. The peak effects (i.e., maximal increase) on CBF after the 10 second and 30 second injections were 217±15% and 297±33% above baseline, respectively. The times to peak effect on CBF were 17±2 seconds and 27±6 seconds, respectively. Effect of Aminophylline Aminophylline (100 mg, administered by slow intravenous injection over 60 seconds) injected 1 minute after 0.4 mg regadenoson in patients undergoing cardiac catheterization, was shown to shorten the duration of the coronary blood flow response to regadenoson as measured by pulsed- wave Doppler ultrasonography [see Overdosage ( 10) ]. Effect of Caffeine Ingestion of caffeine decreases the ability to detect reversible ischemic defects. In a placebo- controlled, parallel group clinical study, patients with known or suspected myocardial ischemia received a baseline rest/stress MPI followed by a second stress MPI. Patients received caffeine or placebo 90 minutes before the second regadenoson stress MPI. Following caffeine administration (200 or 400 mg), the mean number of reversible defects identified was reduced by approximately 60%. This decrease was statistically significant [see Drug Interactions ( 7.1) and Patient Counseling Information ( 17) ]. Hemodynamic Effects In clinical studies, the majority of patients had an increase in heart rate and a decrease in blood pressure within 45 minutes after administration of regadenoson. Maximum hemodynamic changes after regadenoson and ADENOSCAN in Studies 1 and 2 are summarized in Table 5. Table 5 Hemodynamic Effects in Studies 1 and 2 Vital Sign Parameter REGADENOSON N = 1,337 ADENOSCAN N = 678 Heart Rate > 100 bpm 22% 13% Increase > 40 bpm 5% 3% Systolic Blood Pressure < 90 mm Hg 2% 3% Decrease > 35 mm Hg 7% 8% ≥ 200 mm Hg 1.9% 1.9% Increase ≥ 50 mm Hg 0.7% 0.8% ≥ 180 mm Hg and increase of ≥ 20 mm Hg from baseline 4.6% 3.2% Diastolic Blood Pressure < 50 mm Hg 2% 4% Decrease > 25 mm Hg 4% 5% ≥ 115 mm Hg 0.9% 0.9% Increase ≥ 30 mm Hg 0.5% 1.1% Hemodynamic Effects Following Inadequate Exercise In a clinical study, regadenoson was administered for MPI following inadequate exercise stress. More patients with regadenoson administration three minutes following inadequate exercise stress had an increase in heart rate and a decrease in systolic blood pressure compared with regadenoson administered at rest. The changes were not associated with any clinically significant adverse reactions. Maximum hemodynamic changes are presented in Table 6. Table 6 Hemodynamic Effects in Inadequate Exercise Stress Study Vital Sign Parameter Group 1 / MPI 1 Regadenoson 3 minutes following exercise (N=575) Group 2 / MPI 1 Regadenoson 1 hour following exercise (N=567) Heart Rate > 100 bpm 44% 31% Increase > 40 bpm 5% 16% Systolic Blood Pressure < 90 mm Hg 2% 4% Decrease > 35 mm Hg 29% 10% ≥ 200 mm Hg 0.9% 0.4% Increase ≥ 50 mm Hg 2% 0.4% ≥ 180 mm Hg and increase of ≥ 20 mm Hg from baseline 5% 2% Diastolic Blood Pressure < 50 mm Hg 3% 3% Decrease > 25 mm Hg 6% 5% ≥ 115 mm Hg 0.7% 0.4% Increase ≥ 30 mm Hg 2% 1% Respiratory Effects The A 2B and A 3 adenosine receptors have been implicated in the pathophysiology of bronchoconstriction in susceptible individuals (i.e., asthmatics). In in vitro studies, regadenoson has not been shown to have appreciable binding affinity for the A 2B and A 3 adenosine receptors. In a randomized, placebo-controlled clinical trial of 999 patients with a diagnosis, or risk factors for, coronary artery disease and concurrent asthma or COPD, the incidence of respiratory adverse reactions (dyspnea, wheezing) was greater with regadenoson compared to placebo. Moderate (2.5%) or severe (< 1%) respiratory reactions were observed more frequently in the regadenoson group compared to placebo [see Adverse Reactions ( 6.1 ) ]. 12.3 Pharmacokinetics In healthy subjects, the regadenoson plasma concentration-time profile is multi-exponential in nature and best characterized by 3-compartment model. The maximal plasma concentration of regadenoson is achieved within 1 to 4 minutes after injection of regadenoson and parallels the onset of the pharmacodynamic response. The half-life of this initial phase is approximately 2 to 4 minutes. An intermediate phase follows, with a half-life on average of 30 minutes coinciding with loss of the pharmacodynamic effect. The terminal phase consists of a decline in plasma concentration with a half-life of approximately 2 hours [see Clinical Pharmacology ( 12.2) ]. Within the dose range of 0.3–20 µg/kg in healthy subjects, clearance, terminal half-life or volume of distribution do not appear dependent upon the dose. A population pharmacokinetic analysis including data from subjects and patients demonstrated that regadenoson clearance decreases in parallel with a reduction in creatinine clearance and clearance increases with increased body weight. Age, gender, and race have minimal effects on the pharmacokinetics of regadenoson. Specific Populations Renally Impaired Patients: The disposition of regadenoson was studied in 18 patients with various degrees of renal function and in 6 healthy subjects. With increasing renal impairment, from mild (CLcr 50 to < 80 mL/min) to moderate (CLcr 30 to < 50 mL/min) to severe renal impairment (CLcr < 30 mL/min), the fraction of regadenoson excreted unchanged in urine and the renal clearance decreased, resulting in increased elimination half-lives and AUC values compared to healthy subjects (CLcr ≥ 80 mL/min). However, the maximum observed plasma concentrations as well as volumes of distribution estimates were similar across the groups. The plasma concentration- time profiles were not significantly altered in the early stages after dosing when most pharmacologic effects are observed. No dose adjustment is needed in patients with renal impairment. Patients with End Stage Renal Disease: The pharmacokinetics of regadenoson in patients on dialysis has not been assessed; however, in an in vitro study regadenoson was found to be dialyzable. Hepatically Impaired Patients : The influence of hepatic impairment on the pharmacokinetics of regadenoson has not been evaluated. Because greater than 55% of the dose is excreted in the urine as unchanged drug and factors that decrease clearance do not affect the plasma concentration in the early stages after dosing when clinically meaningful pharmacologic effects are observed, no dose adjustment is needed in patients with hepatic impairment. Geriatric Patients: Based on a population pharmacokinetic analysis, age has a minor influence on the pharmacokinetics of regadenoson. No dose adjustment is needed in elderly patients. Metabolism The metabolism of regadenoson is unknown in humans. Incubation with rat, dog, and human liver microsomes as well as human hepatocytes produced no detectable metabolites of regadenoson. Excretion In healthy volunteers, 57% of the regadenoson dose is excreted unchanged in the urine (range 19- 77%), with an average plasma renal clearance around 450 mL/min, i.e., in excess of the glomerular filtration rate. This indicates that renal tubular secretion plays a role in regadenoson elimination."],"indications_and_usage":["1 INDICATIONS AND USAGE Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress (1) ."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Myocardial Ischemia. Fatal cardiac events have occurred. Avoid use in patients with symptoms or signs of acute myocardial ischemia, for example unstable angina or cardiovascular instability, who may be at greater risk. Cardiac resuscitation equipment and trained staff should be available before administration (5.1) . Sinoatrial (SA) and Atrioventricular (AV) Nodal Block. Adenosine receptor agonists, including regadenoson injection, can depress the SA and AV nodes and may cause first-, second- or third-degree AV block, or sinus bradycardia (5.2) . Atrial Fibrillation/Atrial Flutter. New-onset or recurrent atrial fibrillation with rapid ventricular response and atrial flutter have been reported (5.3) . Hypersensitivity, including anaphylaxis, angioedema, cardiac or respiratory arrest, respiratory distress, decreased oxygen saturation, hypotension, throat tightness, urticaria, and rashes have occurred. Have personnel and resuscitative equipment immediately available (5.4). Hypotension. Adenosine receptor agonists, including regadenoson injection, induce vasodilation and hypotension. The risk of serious hypotension may be higher in patients with autonomic dysfunction, stenotic valvular heart disease, pericarditis or pericardial effusions, stenotic carotid artery disease with cerebrovascular insufficiency, or hypovolemia (5.5) . Hypertension. Adenosine receptor agonists, including regadenoson injection, may induce clinically significant increases in blood pressure particularly in patients with a history of hypertension and when the MPI includes low level exercise (5.6) . Bronchoconstriction. Adenosine receptor agonists, including regadenoson injection, may induce dyspnea, bronchoconstriction and respiratory compromise in patients with chronic obstructive pulmonary disease (COPD) or asthma. Resuscitative measures should be available ( 5.7 ). Seizure. regadenoson injection may lower the seizure threshold. New onset or recurrence of convulsive seizures has occurred. Some seizures are prolonged and require urgent anticonvulsive management. Methylxanthine use is not recommended in patients who experience a seizure in association with regadenoson injection (5.8). Cerebrovascular Accident (Stroke). Hemorrhagic and ischemic cerebrovascular accidents have occurred (5.9). 5.1 Myocardial Ischemia Fatal and nonfatal myocardial infarction (MI), ventricular arrhythmias, and cardiac arrest have occurred following regadenoson. Avoid use in patients with symptoms or signs of acute myocardial ischemia, for example unstable angina or cardiovascular instability; these patients may be at greater risk of serious cardiovascular reactions to regadenoson. Cardiac resuscitation equipment and trained staff should be available before administering regadenoson. Adhere to the recommended duration of injection [see Dosage and Administration ( 2 )]. As noted in an animal study, longer injection times may increase the duration and magnitude of increase in coronary blood flow [see Clinical Pharmacology ( 12.2) ]. If serious reactions to regadenoson injection occur, consider the use of aminophylline, an adenosine antagonist, to shorten the duration of increased coronary blood flow induced by regadenoson [see Overdosage ( 10) ]. 5.2 Sinoatrial and Atrioventricular Nodal Block Adenosine receptor agonists, including regadenoson, can depress the SA and AV nodes and may cause first-, second- or third-degree AV block, or sinus bradycardia requiring intervention. In clinical trials first-degree AV block (PR prolongation > 220 msec) developed in 3% of patients within 2 hours of regadenoson administration; transient second-degree AV block with one dropped beat was observed in one patient receiving regadenoson. In post-marketing experience, third-degree heart block and asystole within minutes of regadenoson administration have occurred [see Adverse Reactions ( 6.2) ]. 5.3 Atrial Fibrillation/Atrial Flutter New-onset or recurrent atrial fibrillation with rapid ventricular response and atrial flutter have been reported following regadenoson [see Adverse Reactions ( 6.2) ]. 5.4 Hypersensitivity, Including Anaphylaxis Anaphylaxis, angioedema, cardiac or respiratory arrest, respiratory distress, decreased oxygen saturation, hypotension, throat tightness, urticaria and rashes have occurred. In clinical trials, hypersensitivity reactions were reported in fewer than 1 percent of patients [see Adverse Reactions ( 6.1) ]. Have personnel and resuscitative equipment immediately available. 5.5 Hypotension Adenosine receptor agonists, including regadenoson, induce arterial vasodilation and hypotension. In clinical trials, decreased systolic blood pressure (> 35 mm Hg) was observed in 7% of patients and decreased diastolic blood pressure (> 25 mm Hg) was observed in 4% of patients within 45 minutes of regadenoson administration. The risk of serious hypotension may be higher in patients with autonomic dysfunction, hypovolemia, left main coronary artery stenosis, stenotic valvular heart disease, pericarditis or pericardial effusions, or stenotic carotid artery disease with cerebrovascular insufficiency. In post-marketing experience, syncope, transient ischemic attacks and seizures have been observed [see Adverse Reactions ( 6.2) ]. 5.6 Hypertension Administration of adenosine receptor agonists, including regadenoson, may result in clinically significant increases in blood pressure in some patients. Among patients who experienced an increase in blood pressure in clinical trials, the increase was observed within minutes of regadenoson administration. Most increases resolved within 10 to 15 minutes, but in some cases, increases were observed at 45 minutes following administration [see Clinical Pharmacology ( 12.2) ]. In post-marketing experience, cases of potentially clinically significant hypertension have been reported, particularly with underlying hypertension and when low-level exercise was included in the MPI [see Adverse Reactions ( 6.2) ]. 5.7 Bronchoconstriction Adenosine receptor agonists, including regadenoson, may cause dyspnea, bronchoconstriction, and respiratory compromise. Appropriate bronchodilator therapy and resuscitative measures should be available prior to and following regadenoson administration [see Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.2) , Overdosage ( 10) and Patient Counseling Information ( 17) ]. 5.8 Seizure Regadenoson may lower the seizure threshold; obtain a seizure history. New-onset or recurrence of convulsive seizures has occurred following regadenoson. Some seizures are prolonged and require emergent anticonvulsive management. Aminophylline may increase the risk of seizures associated with regadenoson. Methylxanthine use is not recommended in patients who experience a seizure in association with regadenoson administration. 5.9 Cerebrovascular Accident (Stroke) Hemorrhagic and ischemic cerebrovascular accidents have occurred. Hemodynamic effects of regadenoson including hypotension or hypertension may be associated with these adverse reactions [see Warnings and Precautions ( 5.5) and ( 5.6 ) ].","5.1 Myocardial Ischemia Fatal and nonfatal myocardial infarction (MI), ventricular arrhythmias, and cardiac arrest have occurred following regadenoson. Avoid use in patients with symptoms or signs of acute myocardial ischemia, for example unstable angina or cardiovascular instability; these patients may be at greater risk of serious cardiovascular reactions to regadenoson. Cardiac resuscitation equipment and trained staff should be available before administering regadenoson. Adhere to the recommended duration of injection [see Dosage and Administration ( 2 )]. As noted in an animal study, longer injection times may increase the duration and magnitude of increase in coronary blood flow [see Clinical Pharmacology ( 12.2) ]. If serious reactions to regadenoson injection occur, consider the use of aminophylline, an adenosine antagonist, to shorten the duration of increased coronary blood flow induced by regadenoson [see Overdosage ( 10) ].","5.2 Sinoatrial and Atrioventricular Nodal Block Adenosine receptor agonists, including regadenoson, can depress the SA and AV nodes and may cause first-, second- or third-degree AV block, or sinus bradycardia requiring intervention. In clinical trials first-degree AV block (PR prolongation > 220 msec) developed in 3% of patients within 2 hours of regadenoson administration; transient second-degree AV block with one dropped beat was observed in one patient receiving regadenoson. In post-marketing experience, third-degree heart block and asystole within minutes of regadenoson administration have occurred [see Adverse Reactions ( 6.2) ].","5.3 Atrial Fibrillation/Atrial Flutter New-onset or recurrent atrial fibrillation with rapid ventricular response and atrial flutter have been reported following regadenoson [see Adverse Reactions ( 6.2) ].","5.4 Hypersensitivity, Including Anaphylaxis Anaphylaxis, angioedema, cardiac or respiratory arrest, respiratory distress, decreased oxygen saturation, hypotension, throat tightness, urticaria and rashes have occurred. In clinical trials, hypersensitivity reactions were reported in fewer than 1 percent of patients [see Adverse Reactions ( 6.1) ]. Have personnel and resuscitative equipment immediately available.","5.5 Hypotension Adenosine receptor agonists, including regadenoson, induce arterial vasodilation and hypotension. In clinical trials, decreased systolic blood pressure (> 35 mm Hg) was observed in 7% of patients and decreased diastolic blood pressure (> 25 mm Hg) was observed in 4% of patients within 45 minutes of regadenoson administration. The risk of serious hypotension may be higher in patients with autonomic dysfunction, hypovolemia, left main coronary artery stenosis, stenotic valvular heart disease, pericarditis or pericardial effusions, or stenotic carotid artery disease with cerebrovascular insufficiency. In post-marketing experience, syncope, transient ischemic attacks and seizures have been observed [see Adverse Reactions ( 6.2) ].","5.6 Hypertension Administration of adenosine receptor agonists, including regadenoson, may result in clinically significant increases in blood pressure in some patients. Among patients who experienced an increase in blood pressure in clinical trials, the increase was observed within minutes of regadenoson administration. Most increases resolved within 10 to 15 minutes, but in some cases, increases were observed at 45 minutes following administration [see Clinical Pharmacology ( 12.2) ]. In post-marketing experience, cases of potentially clinically significant hypertension have been reported, particularly with underlying hypertension and when low-level exercise was included in the MPI [see Adverse Reactions ( 6.2) ].","5.7 Bronchoconstriction Adenosine receptor agonists, including regadenoson, may cause dyspnea, bronchoconstriction, and respiratory compromise. Appropriate bronchodilator therapy and resuscitative measures should be available prior to and following regadenoson administration [see Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.2) , Overdosage ( 10) and Patient Counseling Information ( 17) ].","5.8 Seizure Regadenoson may lower the seizure threshold; obtain a seizure history. New-onset or recurrence of convulsive seizures has occurred following regadenoson. Some seizures are prolonged and require emergent anticonvulsive management. Aminophylline may increase the risk of seizures associated with regadenoson. Methylxanthine use is not recommended in patients who experience a seizure in association with regadenoson administration.","5.9 Cerebrovascular Accident (Stroke) Hemorrhagic and ischemic cerebrovascular accidents have occurred. Hemodynamic effects of regadenoson including hypotension or hypertension may be associated with these adverse reactions [see Warnings and Precautions ( 5.5) and ( 5.6 ) ]."],"clinical_studies_table":["
Study 1Study 2
ADENOSCAN – ADENOSCAN Agreement Rate (± SE) 61 ± 3% 64 ± 4%
ADENOSCAN – Regadenoson Agreement Rate (± SE) 62 ± 2% 63 ± 3%
Rate Difference (Regadenoson– ADENOSCAN) (± SE) 95% Confidence Interval 1 ± 4% -7.5, 9.2% -1 ± 5% -11.2, 8.7%
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Regadenoson was negative in the Ames bacterial mutation assay, chromosomal aberration assay in Chinese hamster ovary (CHO) cells, and mouse bone marrow micronucleus assay. Long-term animal studies have not been conducted to evaluate regadenoson’s carcinogenic potential or potential effects on fertility. 13.2 Animal Toxicology and/or Pharmacology Cardiomyopathy Minimal cardiomyopathy (myocyte necrosis and inflammation) was observed in rats following single-dose administration of regadenoson. Increased incidence of minimal cardiomyopathy was observed on day 2 in males at doses of 0.08, 0.2 and 0.8 mg/kg (1/5, 2/5, and 5/5) and in females (2/5) at 0.8 mg/kg. In a separate study in male rats, the mean arterial pressure was decreased by 30 to 50% of baseline values for up to 90 minutes at regadenoson doses of 0.2 and 0.8 mg/kg, respectively. No cardiomyopathy was noted in rats sacrificed 15 days following single administration of regadenoson. The mechanism of the cardiomyopathy induced by regadenoson was not elucidated in this study but was associated with the hypotensive effects of regadenoson. Profound hypotension induced by vasoactive drugs is known to cause cardiomyopathy in rats. Local Irritation Intravenous administration of regadenoson to rabbits resulted in perivascular hemorrhage, vein vasculitis, inflammation, thrombosis and necrosis, with inflammation and thrombosis persisting through day 8 (last observation day). Perivascular administration of regadenoson to rabbits resulted in hemorrhage, inflammation, pustule formation and epidermal hyperplasia, which persisted through day 8 except for the hemorrhage which resolved. Subcutaneous administration of regadenoson to rabbits resulted in hemorrhage, acute inflammation, and necrosis; on day 8 muscle fiber regeneration was observed."],"pharmacodynamics_table":["
Vital Sign ParameterREGADENOSON N = 1,337ADENOSCAN N = 678
Heart Rate
> 100 bpm 22% 13%
Increase > 40 bpm 5% 3%
Systolic Blood Pressure
< 90 mm Hg 2% 3%
Decrease > 35 mm Hg 7% 8%
≥ 200 mm Hg 1.9% 1.9%
Increase ≥ 50 mm Hg 0.7% 0.8%
≥ 180 mm Hg and increase of ≥ 20 mm Hg from baseline 4.6% 3.2%
Diastolic Blood Pressure
< 50 mm Hg 2% 4%
Decrease > 25 mm Hg 4% 5%
≥ 115 mm Hg 0.9% 0.9%
Increase ≥ 30 mm Hg 0.5% 1.1%
","
Vital Sign ParameterGroup 1 / MPI 1Regadenoson 3 minutes following exercise(N=575)Group 2 / MPI 1Regadenoson 1 hour following exercise(N=567)
Heart Rate
> 100 bpm 44% 31%
Increase > 40 bpm 5% 16%
Systolic Blood Pressure
< 90 mm Hg 2% 4%
Decrease > 35 mm Hg 29% 10%
≥ 200 mm Hg 0.9% 0.4%
Increase ≥ 50 mm Hg 2% 0.4%
≥ 180 mm Hg and increase of ≥ 20 mm Hg from baseline 5% 2%
Diastolic Blood Pressure
< 50 mm Hg 3% 3%
Decrease > 25 mm Hg 6% 5%
≥ 115 mm Hg 0.7% 0.4%
Increase ≥ 30 mm Hg 2% 1%
"],"adverse_reactions_table":["
REGADENOSON N = 1,337ADENOSCAN N = 678
Dyspnea 28% 26%
Headache 26% 17%
Flushing 16% 25%
Chest Discomfort 13% 18%
Angina Pectoris or ST Segment Depression 12% 18%
Dizziness 8% 7%
Chest Pain 7% 10%
Nausea 6% 6%
Abdominal Discomfort 5% 2%
Dysgeusia 5% 7%
Feeling Hot 5% 8%
","
REGADENOSON N / N evaluable (%)ADENOSCAN N / N evaluable (%)
Rhythm or conduction abnormalities† 332/1275 (26%) 192/645 (30%)
Rhythm abnormalities 260/1275 (20%) 131/645 (20%)
PACs 86/1274 (7%) 57/645 (9%)
PVCs 179/1274 (14%) 79/645 (12%)
First-degree AV block (PR prolongation > 220 msec) 34/1209 (3%) 43/618 (7%)
Second-degree AV block 1/1209 (0.1%) 9/618 (1%)
AV conduction abnormalities (other than AV blocks) 1/1209 (0.1%) 0/618 (0%)
Ventricular conduction abnormalities 64/1152 (6%) 31/581 (5%)
","
Asthma CohortChronic Obstructive Pulmonary Disease (COPD) Cohort
Regadenoson (N=356)Placebo (N=176)Regadenoson (N=316)Placebo (N=151)
Overall Pre-specified Respiratory Adverse Reaction†12.9%2.3%19.0%4.0%
Dyspnea10.7%1.1%18.0%2.6%
Wheezing3.1%1.1%0.9%0.7%
FEV1 reduction >15%‡1.1%2.9%4.2%5.4%
","
Cardiac Event*Group 1 / MPI 1 Regadenoson 3 minutes following exercise (N=575)Group 2 / MPI 1 Regadenoson 1 hour following exercise (N=567)
17 (3.0%)3 (0.5%)
Holter/12-Lead ECG Abnormality
ST-T Depression (≥ 2 mm)13 (2.3%)2 (0.4%)
ST-T Elevation (≥ 1 mm)3 (0.5%)1 (0.2%)
Acute coronary syndrome1 (0.2%)0
Myocardial infarction1 (0.2%)0
*A clinically significant cardiac event was defined as any of the following events found on the Holter ECG/12-lead ECG within one hour after regadenoson administration: ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, Torsade de Pointes, ventricular flutter); ST-T depression (≥ 2 mm); ST-T elevation (≥ 1 mm); AV block (2:1 AV block, AV Mobitz I, AV Mobitz II, complete heart block); sinus arrest > 3 seconds in duration Or a Treatment Emergent Adverse Event (TEAE) per the MedDRA SMQ (narrow Scope) for myocardial infarction Or a TEAE preferred term (PT) of angina unstable within 24 hours of regadenoson administration.
","
REGADENOSON N = 1,337ADENOSCAN N = 678
Dyspnea 28% 26%
Headache 26% 17%
Flushing 16% 25%
Chest Discomfort 13% 18%
Angina Pectoris or ST Segment Depression 12% 18%
Dizziness 8% 7%
Chest Pain 7% 10%
Nausea 6% 6%
Abdominal Discomfort 5% 2%
Dysgeusia 5% 7%
Feeling Hot 5% 8%
","
REGADENOSON N / N evaluable (%)ADENOSCAN N / N evaluable (%)
Rhythm or conduction abnormalities† 332/1275 (26%) 192/645 (30%)
Rhythm abnormalities 260/1275 (20%) 131/645 (20%)
PACs 86/1274 (7%) 57/645 (9%)
PVCs 179/1274 (14%) 79/645 (12%)
First-degree AV block (PR prolongation > 220 msec) 34/1209 (3%) 43/618 (7%)
Second-degree AV block 1/1209 (0.1%) 9/618 (1%)
AV conduction abnormalities (other than AV blocks) 1/1209 (0.1%) 0/618 (0%)
Ventricular conduction abnormalities 64/1152 (6%) 31/581 (5%)
","
Asthma CohortChronic Obstructive Pulmonary Disease (COPD) Cohort
Regadenoson (N=356)Placebo (N=176)Regadenoson (N=316)Placebo (N=151)
Overall Pre-specified Respiratory Adverse Reaction†12.9%2.3%19.0%4.0%
Dyspnea10.7%1.1%18.0%2.6%
Wheezing3.1%1.1%0.9%0.7%
FEV1 reduction >15%‡1.1%2.9%4.2%5.4%
","
Cardiac Event*Group 1 / MPI 1 Regadenoson 3 minutes following exercise (N=575)Group 2 / MPI 1 Regadenoson 1 hour following exercise (N=567)
17 (3.0%)3 (0.5%)
Holter/12-Lead ECG Abnormality
ST-T Depression (≥ 2 mm)13 (2.3%)2 (0.4%)
ST-T Elevation (≥ 1 mm)3 (0.5%)1 (0.2%)
Acute coronary syndrome1 (0.2%)0
Myocardial infarction1 (0.2%)0
*A clinically significant cardiac event was defined as any of the following events found on the Holter ECG/12-lead ECG within one hour after regadenoson administration: ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, Torsade de Pointes, ventricular flutter); ST-T depression (≥ 2 mm); ST-T elevation (≥ 1 mm); AV block (2:1 AV block, AV Mobitz I, AV Mobitz II, complete heart block); sinus arrest > 3 seconds in duration Or a Treatment Emergent Adverse Event (TEAE) per the MedDRA SMQ (narrow Scope) for myocardial infarction Or a TEAE preferred term (PT) of angina unstable within 24 hours of regadenoson administration.
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Drug Interaction Patients should be instructed to avoid consumption of any products containing methylxanthines, including caffeinated coffee, tea or other caffeinated beverages, caffeine-containing drug products, aminophylline and theophylline for at least 12 hours before a scheduled radionuclide MPI [see Warnings and Precautions ( 5.8) and Clinical Pharmacology ( 12.2) ]. Cardiovascular Advise patients that they may be at increased risk of fatal and nonfatal heart attacks, abnormal heart rhythms, cardiac arrest, significant increase or decrease in blood pressure, or cerebrovascular accidents (stroke) with the use of regadenoson injection [see Warnings and Precautions ( 5. 1), ( 5.3) , ( 5.5) , ( 5.6) and ( 5.9) ]. Hypersensitivity Inform patients that allergic reactions have been reported with regadenoson injection. Advise patients how to recognize such a reaction and when to seek medical attention [see Warnings and Precautions ( 5.4) ]. Respiratory Advise patients with COPD or asthma about the need for administration of pre- and post-study bronchodilator therapy and to call their clinician if they experience any shortness of breath or difficulty breathing following an MPI study with regadenoson injection [see Warnings and Precautions ( 5.7) ]. Seizures Advise patients that they may be at increased risk of seizures. Question patients about a history of seizures [see Warnings and Precautions ( 5.8) ]. Lactation Advise a woman to pump and discard breast milk for 10 hours after regadenoson injection administration [see Use in Specific Populations ( 8.2) ]. ADENOSCAN ® are registered trademarks of Astellas US LLC. All other trademarks and registered trademarks are the property of their respective owners. Rx Only Distributor: Dr. Reddy’s Laboratories Inc., Princeton, NJ 08540 Made in India Issued: 1122"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION The recommended dose of regadenoson injection is 5 mL (0.4 mg regadenoson) administered as an intravenous injection within 10 seconds. · Patients should be instructed to avoid consumption of any products containing methylxanthines, including caffeinated coffee, tea or other caffeinated beverages, caffeine-containing drug products, aminophylline and theophylline for at least 12 hours before a scheduled radionuclide MPI [see Drug Interactions ( 7.1) and Clinical Pharmacology ( 12.2) ] Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer regadenoson injection if it contains particulate matter or is discolored. Aminister regadenoson injection as an intravenous injection within 10 seconds into a peripheral vein using a 22 gauge or larger catheter or needle.· Administer a 5 mL saline flush immediately after the injection of regadenoson.· Administer the radionuclide myocardial perfusion imaging agent 10–20 seconds after the saline flush. The radionuclide may be injected directly into the same catheter as regadenoson injection. · The recommended dose of regadenoson injection is 5 mL (0.4 mg regadenoson) administered as an intravenous injection within 10 seconds; followed immediately by saline flush and radiopharmaceutical (2) ."],"spl_product_data_elements":["Regadenoson Regadenoson Regadenoson Anhydrous Regadenoson Anhydrous Sodium Phosphate, Dibasic, Dihydrate Sodium Phosphate, Monobasic, Monohydrate PROPYLENE GLYCOL Edetate Disodium Water carton pfs structure"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Single-dose pre-filled syringe: clear, colorless solution containing regadenoson 0.4 mg/5 mL (0.08 mg/mL). · Injection: Single-dose pre-filled syringe: 0.4 mg/5 mL (0.08 mg/mL) (3) ."],"clinical_pharmacology_table":["
Vital Sign ParameterREGADENOSON N = 1,337ADENOSCAN N = 678
Heart Rate
> 100 bpm 22% 13%
Increase > 40 bpm 5% 3%
Systolic Blood Pressure
< 90 mm Hg 2% 3%
Decrease > 35 mm Hg 7% 8%
≥ 200 mm Hg 1.9% 1.9%
Increase ≥ 50 mm Hg 0.7% 0.8%
≥ 180 mm Hg and increase of ≥ 20 mm Hg from baseline 4.6% 3.2%
Diastolic Blood Pressure
< 50 mm Hg 2% 4%
Decrease > 25 mm Hg 4% 5%
≥ 115 mm Hg 0.9% 0.9%
Increase ≥ 30 mm Hg 0.5% 1.1%
","
Vital Sign ParameterGroup 1 / MPI 1Regadenoson 3 minutes following exercise(N=575)Group 2 / MPI 1Regadenoson 1 hour following exercise(N=567)
Heart Rate
> 100 bpm 44% 31%
Increase > 40 bpm 5% 16%
Systolic Blood Pressure
< 90 mm Hg 2% 4%
Decrease > 35 mm Hg 29% 10%
≥ 200 mm Hg 0.9% 0.4%
Increase ≥ 50 mm Hg 2% 0.4%
≥ 180 mm Hg and increase of ≥ 20 mm Hg from baseline 5% 2%
Diastolic Blood Pressure
< 50 mm Hg 3% 3%
Decrease > 25 mm Hg 6% 5%
≥ 115 mm Hg 0.7% 0.4%
Increase ≥ 30 mm Hg 2% 1%
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no available data on regadenoson use in pregnant women to inform a drug-associated risk. In animal reproduction studies, adverse developmental outcomes were observed with the administration of regadenoson to pregnant rats and rabbits during organogenesis only at doses that produced maternal toxicity (see Data). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Reproductive studies in rats showed that regadenoson doses 10 and 20 times the maximum recommended human dose (MRHD) based on body surface area caused reduced fetal body weights and significant ossification delays in fore- and hind limb phalanges and metatarsals; maternal toxicity also occurred at these doses. Skeletal variations were increased in all treated groups. In rabbits, maternal toxicity occurred at regadenoson doses administered during organogenesis at 4 times the MRHD; however, there were no teratogenic effects in offspring at this dose. At higher doses, 12 and 20 times the MRHD, maternal toxicity occurred along with increased embryo-fetal loss and fetal malformations. 8.2 Lactation Risk Summary There is no information on the presence of regadenoson in human milk, the effects on the breastfed infant, or the effects on milk production. Because of the potential risk of serious cardiac reactions in the breastfed infant, advise the nursing mother to pump and discard breast milk for 10 hours after administration of regadenoson. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. 8.5 Geriatric Use Of the 1,337 patients receiving regadenoson in Studies 1 and 2, 56% were 65 years of age and over and 24% were 75 years of age and over. Older patients (≥ 75 years of age) had a similar adverse event profile compared to younger patients (< 65 years of age), but had a higher incidence of hypotension (2% vs. ≤ 1%). 8.6 Renal Impairment No dose adjustment is needed in patients with renal impairment including patients with end stage renal disease and/or dependent on dialysis [see Pharmacokinetics ( 12.3 ) ].","8.6 Renal Impairment No dose adjustment is needed in patients with renal impairment including patients with end stage renal disease and/or dependent on dialysis [see Pharmacokinetics ( 12.3 ) ]."],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology Cardiomyopathy Minimal cardiomyopathy (myocyte necrosis and inflammation) was observed in rats following single-dose administration of regadenoson. Increased incidence of minimal cardiomyopathy was observed on day 2 in males at doses of 0.08, 0.2 and 0.8 mg/kg (1/5, 2/5, and 5/5) and in females (2/5) at 0.8 mg/kg. In a separate study in male rats, the mean arterial pressure was decreased by 30 to 50% of baseline values for up to 90 minutes at regadenoson doses of 0.2 and 0.8 mg/kg, respectively. No cardiomyopathy was noted in rats sacrificed 15 days following single administration of regadenoson. The mechanism of the cardiomyopathy induced by regadenoson was not elucidated in this study but was associated with the hypotensive effects of regadenoson. Profound hypotension induced by vasoactive drugs is known to cause cardiomyopathy in rats. Local Irritation Intravenous administration of regadenoson to rabbits resulted in perivascular hemorrhage, vein vasculitis, inflammation, thrombosis and necrosis, with inflammation and thrombosis persisting through day 8 (last observation day). Perivascular administration of regadenoson to rabbits resulted in hemorrhage, inflammation, pustule formation and epidermal hyperplasia, which persisted through day 8 except for the hemorrhage which resolved. Subcutaneous administration of regadenoson to rabbits resulted in hemorrhage, acute inflammation, and necrosis; on day 8 muscle fiber regeneration was observed."],"package_label_principal_display_panel":["PACKAGE LABEL PRINCIPAL DISPLAY PANEL SECTION PFS label for Regadenoson Injection 0.4 mg/5 ml (0.08 mg/ml)","Unvarnished Area Consists of: 2D Barcode, Lot Number, Expiry Date and Serial Number Carton Label for Regadenoson Injection 0.4 mg/5 ml (0.08 mg/ml)"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Regadenoson was negative in the Ames bacterial mutation assay, chromosomal aberration assay in Chinese hamster ovary (CHO) cells, and mouse bone marrow micronucleus assay. Long-term animal studies have not been conducted to evaluate regadenoson’s carcinogenic potential or potential effects on fertility."]},"tags":[],"safety":{"safetySignals":[{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"509 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"408 reports"},{"date":"","signal":"INJECTION SITE EXTRAVASATION","source":"FDA FAERS","actionTaken":"361 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"357 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"315 reports"},{"date":"","signal":"HYPOTENSION","source":"FDA FAERS","actionTaken":"312 reports"},{"date":"","signal":"CARDIAC ARREST","source":"FDA FAERS","actionTaken":"283 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"272 reports"},{"date":"","signal":"SEIZURE","source":"FDA FAERS","actionTaken":"251 reports"},{"date":"","signal":"CHEST PAIN","source":"FDA FAERS","actionTaken":"230 reports"}],"drugInteractions":[{"drug":"Methylxanthines (caffeine, aminophylline, theophylline)","severity":"Moderate","mechanism":"Non-specific adenosine receptor antagonists that interfere with vasodilation activity","management":"Avoid consumption of products containing methylxanthines and drugs containing theophylline or aminophylline for at least 12 hours before regadenoson administration","clinicalEffect":"Interfere with the activity of regadenoson injection"},{"drug":"Aminophylline","severity":"Moderate","mechanism":"Adenosine receptor antagonist","management":"May be used to attenuate severe and/or persistent adverse reactions","clinicalEffect":"Can attenuate severe or persistent adverse reactions to regadenoson"},{"drug":"Dipyridamole","severity":"Moderate","mechanism":"May increase activity of regadenoson","management":"Withhold dipyridamole for at least two days prior to regadenoson injection administration when possible","clinicalEffect":"May increase the activity of regadenoson injection"},{"drug":"Beta-blockers, calcium channel blockers, ACE inhibitors, nitrates, cardiac glycosides, angiotensin receptor blockers","severity":"Low","mechanism":"No reported adverse interactions","management":"No specific management required; regadenoson administered without reported issues in clinical studies","clinicalEffect":"No reported adverse reactions or apparent effects on efficacy"}],"commonSideEffects":[{"effect":"Headache","drugRate":"16.5%","placeboRate":"","totalAtRisk":934,"totalAffected":154,"trialsReporting":4},{"effect":"Dyspnoea","drugRate":"14.9%","placeboRate":"","totalAtRisk":834,"totalAffected":124,"trialsReporting":3},{"effect":"Shortness of Breath","drugRate":"48.0%","placeboRate":"","totalAtRisk":100,"totalAffected":48,"trialsReporting":1},{"effect":"Flushing","drugRate":"19.6%","placeboRate":"","totalAtRisk":230,"totalAffected":45,"trialsReporting":2},{"effect":"Angina pectoris","drugRate":"5.0%","placeboRate":"","totalAtRisk":721,"totalAffected":36,"trialsReporting":2},{"effect":"Chest discomfort","drugRate":"14.3%","placeboRate":"","totalAtRisk":230,"totalAffected":33,"trialsReporting":2},{"effect":"Dizziness","drugRate":"14.3%","placeboRate":"","totalAtRisk":230,"totalAffected":33,"trialsReporting":2},{"effect":"Nausea","drugRate":"9.6%","placeboRate":"","totalAtRisk":230,"totalAffected":22,"trialsReporting":2},{"effect":"Chest pain","drugRate":"7.1%","placeboRate":"","totalAtRisk":113,"totalAffected":8,"trialsReporting":1},{"effect":"Stomach discomfort","drugRate":"6.2%","placeboRate":"","totalAtRisk":113,"totalAffected":7,"trialsReporting":1},{"effect":"Chest Pain","drugRate":"7.0%","placeboRate":"","totalAtRisk":100,"totalAffected":7,"trialsReporting":1},{"effect":"Abdominal discomfort","drugRate":"5.3%","placeboRate":"","totalAtRisk":113,"totalAffected":6,"trialsReporting":1},{"effect":"Abdominal pain upper","drugRate":"5.3%","placeboRate":"","totalAtRisk":113,"totalAffected":6,"trialsReporting":1},{"effect":"Dysgeusia","drugRate":"3.5%","placeboRate":"","totalAtRisk":113,"totalAffected":4,"trialsReporting":1},{"effect":"Back pain","drugRate":"4.0%","placeboRate":"","totalAtRisk":100,"totalAffected":4,"trialsReporting":1},{"effect":"Feeling hot","drugRate":"2.7%","placeboRate":"","totalAtRisk":113,"totalAffected":3,"trialsReporting":1}],"contraindications":["Second- or third-degree AV block unless patient has functioning artificial pacemaker","Sinus node dysfunction unless patient has functioning artificial pacemaker"],"specialPopulations":{"Pregnancy":"No available data on regadenoson use in pregnant women. Animal studies showed adverse developmental outcomes (reduced fetal body weights, ossification delays) in rats at doses 10-20 times MRHD and in rabbits at doses 12-20 times MRHD, but only with concurrent maternal toxicity. Background risk of major birth defects is 2-4% and miscarriage is 15-20% in clinically recognized pregnancies.","Geriatric use":"56% of study patients were ≥65 years and 24% were ≥75 years. Older patients (≥75 years) had similar adverse event profile to younger patients (<65 years) but had higher incidence of hypotension (2% vs. ≤1%).","Paediatric use":"Safety and effectiveness in pediatric patients have not been established.","Renal impairment":"No dose adjustment is needed in patients with renal impairment including patients with end stage renal disease and/or dependent on dialysis.","Hepatic impairment":"Not addressed in provided text."}},"trials":[],"_chembl":null,"aliases":[],"patents":[{"applNo":"N022161","source":"FDA Orange Book","status":"Active","expires":"Feb 2, 2027","territory":"US","drugProduct":false,"patentNumber":"8106183","drugSubstance":true},{"applNo":"N022161","source":"FDA Orange Book","status":"Active","expires":"Feb 2, 2027","territory":"US","drugProduct":true,"patentNumber":"RE47301","drugSubstance":false}],"pricing":[],"_fixedAt":"2026-03-30T11:28:32.804767","_sources":{"_fda":{"url":"","method":"api_direct","source":"FDA OpenFDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:55:38.749083+00:00"},"trials":{"url":"https://clinicaltrials.gov/search?intr=Regadenoson","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:37:09.583595+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:37:09.583476+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Regadenoson","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:37:23.790400+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"Haiku strategic summary","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T07:55:46.583339+00:00"},"mechanism":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T08:37:03.640478+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:37:22.407802+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:37:08.090455+00:00"},"pharmacokinetics":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T08:37:03.640499+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Regadenoson","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:37:23.102501+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:37:24.785514+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku extraction","aiModel":"claude-haiku-4-5","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:55:46.583295+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Adenosine A2a receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:37:23.790118+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:55:46.583336+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3989695/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:37:23.695799+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:55:46.583327+00:00"}},"offLabel":[],"timeline":[{"date":"20240822","type":"positive","milestone":"FDA approval — INDIES PHARMA","regulator":"FDA","description":""},{"date":"20220523","type":"positive","milestone":"FDA approval — IMS LTD","regulator":"FDA","description":""},{"date":"20230404","type":"positive","milestone":"FDA approval — MYLAN","regulator":"FDA","description":""},{"date":"20221026","type":"positive","milestone":"FDA approval — EUGIA PHARMA","regulator":"FDA","description":""},{"date":"20220831","type":"positive","milestone":"FDA approval — HOSPIRA","regulator":"FDA","description":""}],"_dailymed":{"setId":"5095ab40-8503-46db-9b08-6a36f05fb5d9","title":"REGADENOSON INJECTION, SOLUTION [INDIES PHARMA JAMAICA LIMITED]"},"aiSummary":"Regadenoson is a selective A2A adenosine receptor agonist indicated for radionuclide myocardial perfusion imaging in patients unable to exercise. It demonstrates rapid onset (1-4 minutes) with a short initial half-life (2-4 minutes) and is primarily renally excreted unchanged. Key risks include contraindication in patients with second- or third-degree AV block or sinus node dysfunction without pacemakers, and significant interactions with methylxanthines that must be avoided for 12 hours prior to administration. The drug's pharmacokinetics are minimally affected by age, gender, or race, with dose adjustment unnecessary even in renal or hepatic impairment.","ecosystem":[],"mechanism":{"target":"A2A adenosine receptor","novelty":"best-in-class","modality":"Small molecule","drugClass":"Adenosine receptor agonist","explanation":"Regadenoson is a low affinity agonist for the A2A adenosine receptor with a Ki of approximately 1.3 µM, demonstrating at least 10-fold lower affinity for the A1 adenosine receptor (Ki > 16.5 µM) and weak or no affinity for A2B and A3 adenosine receptors. Activation of the A2A adenosine receptor by regadenoson produces coronary vasodilation and increases coronary blood flow. This mechanism enables its use as a pharmacologic stress agent for cardiac imaging in patients unable to undergo adequate exercise stress.","oneSentence":"Regadenoson is a low affinity A2A adenosine receptor agonist that produces coronary vasodilation and increases coronary blood flow.","technicalDetail":"Regadenoson is a low-affinity A2A adenosine receptor agonist with Ki ≈1.3 µM, demonstrating >10-fold selectivity over A1 receptors and minimal affinity for A2B and A3 subtypes. A2A receptor activation on coronary vascular endothelium and smooth muscle increases intracellular cAMP through Gs-protein coupling, promoting vasodilation. The resulting increase in coronary blood flow creates diagnostic stress conditions equivalent to exercise-induced hyperemia, enabling detection of flow-limiting coronary stenoses via radionuclide perfusion imaging."},"_scrapedAt":"2026-03-27T23:28:06.654Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Regadenoson","title":"Regadenoson","extract":"Regadenoson, sold under the brand name Lexiscan among others, is an A2A adenosine receptor agonist that is a coronary vasodilator that is commonly used in pharmacologic stress testing. It produces hyperemia quickly and maintains it for a duration that is useful for radionuclide myocardial perfusion imaging. The selective nature of the drug makes it preferable to other stress agents such as adenosine, which are less selective and therefore cause more side-effects."},"commercial":{"launchDate":"2022","annualCostUS":"$1,500-$2,000/yr","currentRevenue":"$300M","peakSalesEstimate":"$500M"},"references":[],"_validation":{"fieldsValidated":6,"lastValidatedAt":"2026-04-20T08:37:06.840549+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"name":"Adenosine (Adenocard)","company":"Astellas Pharma","advantage":"Longer clinical history, direct adenosine receptor agonist with more extensive safety data in cardiac stress testing"},{"name":"Dipyridamole (Persantine)","company":"Boehringer Ingelheim","advantage":"Older alternative that increases endogenous adenosine; lower cost, useful in patients with contraindications to direct adenosine agents"},{"name":"Dobutamine (Dobutrex)","company":"Hospira/Pfizer","advantage":"Beta-adrenergic agonist alternative for stress testing; preferred in patients with reactive airway disease or AV block"},{"name":"Exercise Stress Testing","company":"N/A","advantage":"Non-pharmacologic gold standard when patient is able to exercise; provides additional functional and hemodynamic data"}],"indications":{"approved":[{"name":"Myocardial Perfusion Imaging Adjunct","diseaseId":"myocardial-perfusion-imaging-adjunct","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["generics(13)","patents(2)"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06854458","phase":"NA","title":"The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-06-27","conditions":"Ischemic Heart Disease (IHD), Cardiac Magnetic Resonance Imaging, Myocardial Blood Flow","enrollment":1000},{"nctId":"NCT03331380","phase":"NA","title":"Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2018-01-05","conditions":"CAD","enrollment":2950},{"nctId":"NCT06814587","phase":"","title":"Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-07-01","conditions":"Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)","enrollment":15},{"nctId":"NCT03505736","phase":"","title":"Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-06-21","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":25},{"nctId":"NCT04316676","phase":"NA","title":"The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-06-16","conditions":"Coronary Artery Disease","enrollment":20},{"nctId":"NCT05583721","phase":"PHASE2","title":"Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-10-10","conditions":"Sickle Cell Disease","enrollment":40},{"nctId":"NCT04604782","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients","status":"RECRUITING","sponsor":"GE Healthcare","startDate":"2021-05-20","conditions":"Myocardial Ischemia, Coronary Artery Disease","enrollment":54},{"nctId":"NCT01719016","phase":"","title":"Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cincinnati","startDate":"2010-08","conditions":"Coronary Artery Disease","enrollment":68},{"nctId":"NCT06246188","phase":"","title":"Use of Stress-CMR Using Regadenoson and GE-267 in Adult Patients with Known or Suspected Coronary Artery Disease","status":"NOT_YET_RECRUITING","sponsor":"German Heart Institute","startDate":"2025-06-01","conditions":"Coronary Artery Disease","enrollment":80},{"nctId":"NCT04606069","phase":"PHASE1, PHASE2","title":"Treat COVID-19 Patients With Regadenoson","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2021-05-06","conditions":"COVID-19, Lung Inflammation","enrollment":5},{"nctId":"NCT03102125","phase":"PHASE4","title":"Allograft Dysfunction in Heart Transplant","status":"RECRUITING","sponsor":"Paul Kim","startDate":"2019-10-01","conditions":"Heart Transplant Failure and Rejection","enrollment":376},{"nctId":"NCT00837369","phase":"PHASE1","title":"Regadenoson R-T Perfusion Imaging Trial","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2009-04-07","conditions":"Coronary Artery Disease, Myocardial Perfusion Abnormalities","enrollment":100},{"nctId":"NCT06735521","phase":"","title":"Cardiac Magnetic Resonance Stress-perfusion Study in Patinets with Fontan Circulation","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2024-04-15","conditions":"Univentricular Heart, Microvascular Dysfunction, Heart Failure","enrollment":30},{"nctId":"NCT01334918","phase":"PHASE2","title":"A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-04-26","conditions":"Coronary Artery Disease (CAD)","enrollment":124},{"nctId":"NCT00826280","phase":"PHASE3","title":"Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-03-24","conditions":"Coronary Artery Disease (CAD)","enrollment":347},{"nctId":"NCT01489176","phase":"PHASE3","title":"Regadenoson Real Time Perfusion Imaging Trial-Optison","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2012-07-31","conditions":"Coronary Artery Disease, Myocardial Perfusion Abnormalities","enrollment":50},{"nctId":"NCT02130453","phase":"PHASE4","title":"Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-09-30","conditions":"Ischemia","enrollment":161},{"nctId":"NCT04521569","phase":"EARLY_PHASE1","title":"Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2020-06-22","conditions":"Lung Transplant","enrollment":47},{"nctId":"NCT01566890","phase":"NA","title":"Microvascular Blood Flow in Sickle Cell Anemia","status":"COMPLETED","sponsor":"Versiti Blood Health","startDate":"2012-07","conditions":"Sickle Cell Disease, Sickle Cell Anemia","enrollment":91},{"nctId":"NCT04465526","phase":"","title":"The Influence of Coronary Chronic Total Occlusion on Myocardial Perfusion on Computed Tomography","status":"COMPLETED","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2020-02-01","conditions":"Coronary Occlusion, Myocardial Ischemia, Myocardial Perfusion Imaging","enrollment":27},{"nctId":"NCT03971734","phase":"PHASE1","title":"Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-12-06","conditions":"High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma","enrollment":7},{"nctId":"NCT03354273","phase":"PHASE3","title":"An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2018-06-05","conditions":"Coronary Artery Disease (CAD)","enrollment":730},{"nctId":"NCT05813210","phase":"NA","title":"Myocardial Ischemia Detection With a Combined Cardiovascular Magnetic Resonance and Biomarker Protocol","status":"NOT_YET_RECRUITING","sponsor":"Kantonsspital Olten","startDate":"2023-05-01","conditions":"Myocardial Ischemia Demand","enrollment":772},{"nctId":"NCT01250496","phase":"PHASE4","title":"Study With Aminophylline to Attenuate of the Side Effects of Regadenoson","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2010-11","conditions":"Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan","enrollment":248},{"nctId":"NCT03064295","phase":"","title":"Whole-Heart Myocardial Blood Flow Quantification Using MRI","status":"UNKNOWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-03-01","conditions":"Coronary Artery Disease, Coronary Microvascular Disease","enrollment":160},{"nctId":"NCT01336140","phase":"PHASE4","title":"Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2011-06","conditions":"Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson","enrollment":300},{"nctId":"NCT03800862","phase":"","title":"The Evaluation of the Roles of New Cardiac Imaging in Patients With Chest Pain","status":"TERMINATED","sponsor":"Lancaster General Hospital","startDate":"2019-03-27","conditions":"Cardiology, Radiology, Stenoses","enrollment":14},{"nctId":"NCT01842035","phase":"NA","title":"Heart Rate Response to Regadenoson and Sudden Cardiac Death","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2013-02","conditions":"Left Ventricular Systolic Dysfunction, Sudden Cardiac Death","enrollment":90},{"nctId":"NCT01026012","phase":"NA","title":"Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2009-12","conditions":"Cardiac Function","enrollment":40},{"nctId":"NCT03338504","phase":"","title":"Determining the Mechanism of Myocardial Injury and Role of Coronary Disease in Type 2 Myocardial Infarction","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2017-10-23","conditions":"Myocardial Infarction, Acute, Myocardial Ischemia, Myocardial Injury","enrollment":100},{"nctId":"NCT03236311","phase":"PHASE2","title":"A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-10-12","conditions":"Microvascular Coronary Artery Disease","enrollment":10},{"nctId":"NCT01044901","phase":"","title":"Cardiovascular Complications of Sickle Cell Disease","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2009-03","conditions":"Sickle Cell Disease","enrollment":51},{"nctId":"NCT03449888","phase":"","title":"Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2018-07-01","conditions":"Veterans Referred to the St. Louis VAMC Stress Tes","enrollment":133},{"nctId":"NCT02749045","phase":"NA","title":"Simultaneous Assessment of FFR and SPECT","status":"TERMINATED","sponsor":"Prem Soman","startDate":"2016-07","conditions":"Coronary Artery Disease","enrollment":27},{"nctId":"NCT03170817","phase":"","title":"Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-03-29","conditions":"Coronary Artery Disease","enrollment":15},{"nctId":"NCT05081115","phase":"","title":"Stress Echo 2030: the Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging","status":"RECRUITING","sponsor":"Fatebenefratelli Hospital","startDate":"2021-04-01","conditions":"Coronary Artery Disease, Heart Failure, Hypertrophic Cardiomyopathy","enrollment":10000},{"nctId":"NCT01655524","phase":"PHASE4","title":"The Impact of the Routine Aminophylline Administration Following Regadenoson Stress on SPECT Myocardial Perfusion","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2012-07","conditions":"Coronary Artery Disease","enrollment":""},{"nctId":"NCT00871260","phase":"PHASE4","title":"Stress Testing and Cardiac Magnetic Resonance","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2009-04","conditions":"Coronary Disease","enrollment":20},{"nctId":"NCT01969916","phase":"NA","title":"Stress CT Perfusion in Patients With Chest Pain","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-06","conditions":"Coronary Artery Disease","enrollment":150},{"nctId":"NCT02589977","phase":"PHASE4","title":"Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF","status":"COMPLETED","sponsor":"Marvin W. Kronenberg, M.D.","startDate":"2015-11","conditions":"Heart Failure, Diastolic, Diastolic Heart Failure, Hypertension","enrollment":55},{"nctId":"NCT02220634","phase":"NA","title":"Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension","status":"TERMINATED","sponsor":"National Jewish Health","startDate":"2014-08","conditions":"Pulmonary Hypertension","enrollment":10},{"nctId":"NCT04600115","phase":"EARLY_PHASE1","title":"New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)","status":"UNKNOWN","sponsor":"University of Utah","startDate":"2017-03-03","conditions":"MRI Scans","enrollment":100},{"nctId":"NCT03249272","phase":"PHASE4","title":"Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve","status":"TERMINATED","sponsor":"Duke University","startDate":"2017-09-05","conditions":"Hypertrophic Cardiomyopathy, Non-ischemic Dilated Cardiomyopathy, Microvascular Ischaemia of Myocardium","enrollment":31},{"nctId":"NCT02608944","phase":"NA","title":"Comparison of Quantitative MRI Perfusion Methods With Quantitative PET Perfusion Imaging","status":"WITHDRAWN","sponsor":"University of Utah","startDate":"2012-09-30","conditions":"MRI Scans","enrollment":""},{"nctId":"NCT04475094","phase":"","title":"Impact of Coronary Artery Stenting on Quantitative Myocardial Blood Flow and Health Status","status":"UNKNOWN","sponsor":"Cardiovascular Imaging Technologies","startDate":"2019-12-23","conditions":"Coronary Artery Disease","enrollment":75},{"nctId":"NCT03072589","phase":"PHASE1","title":"Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation","status":"UNKNOWN","sponsor":"Christine Lau, MD","startDate":"2017-11-30","conditions":"Lung Transplant","enrollment":21},{"nctId":"NCT02697877","phase":"","title":"Assessment of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2016-02","conditions":"Coronary Artery Disease","enrollment":183},{"nctId":"NCT03917199","phase":"","title":"Utility of Regadenoson Low-dose Dynamic Computed Tomography for Myocardial Perfusion Assesment (ULYSSES Study).","status":"COMPLETED","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2016-11","conditions":"Myocardial Perfusion Imaging, Computed Tomography, Coronary Artery Disease","enrollment":60},{"nctId":"NCT01518777","phase":"NA","title":"Reducing Radioisotope Dose: the Half-Dose CZT Study","status":"COMPLETED","sponsor":"S.M.Chang, MD","startDate":"2012-01","conditions":"Coronary Artery Disease","enrollment":74},{"nctId":"NCT01655043","phase":"PHASE2","title":"Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2012-09","conditions":"Myocardial Ischemia","enrollment":20},{"nctId":"NCT03103061","phase":"PHASE2","title":"Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography With a 3rd Generation Dual Source CT System","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2016-02-09","conditions":"Cardiovascular Diseases, Coronary Artery Disease","enrollment":24},{"nctId":"NCT03976921","phase":"NA","title":"Impact of Stress CT Myocardial Perfusion on Downstream Resources and Prognosis","status":"UNKNOWN","sponsor":"Centro Cardiologico Monzino","startDate":"2019-06-01","conditions":"Coronary Artery Disease, Myocardial Ischemia","enrollment":2000},{"nctId":"NCT02560467","phase":"NA","title":"Perfusion Imaging With Myocardial Contrast Echocardiography in HCM","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2015-12-01","conditions":"Hypertrophic Cardiomyopathy","enrollment":10},{"nctId":"NCT03101696","phase":"","title":"Determination of Coronarphysiological Parameters With the Method of Thermodillution","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2017-02-05","conditions":"Coronary Artery Stenosis of Unclear Hemodynamic Relevance","enrollment":50},{"nctId":"NCT01433705","phase":"PHASE1","title":"Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2011-11","conditions":"Heart Disease","enrollment":70},{"nctId":"NCT02389738","phase":"EARLY_PHASE1","title":"Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-02","conditions":"Blood Brain Barrier Defect","enrollment":6},{"nctId":"NCT01109992","phase":"PHASE4","title":"Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-02","conditions":"Coronary Artery Disease","enrollment":43},{"nctId":"NCT00763035","phase":"EARLY_PHASE1","title":"Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2009-01","conditions":"Coronary Artery Disease, Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":14},{"nctId":"NCT02115308","phase":"PHASE4","title":"Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging","status":"COMPLETED","sponsor":"Timothy M. Bateman","startDate":"2014-09-03","conditions":"Coronary Artery Disease","enrollment":40},{"nctId":"NCT01949844","phase":"NA","title":"Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies","status":"COMPLETED","sponsor":"Daniel S. Berman","startDate":"2014-05-16","conditions":"Coronary Artery Disease, CAD","enrollment":44},{"nctId":"NCT01919450","phase":"PHASE4","title":"Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation","status":"COMPLETED","sponsor":"Timothy M. Bateman, MD","startDate":"2013-07","conditions":"Myocardial Blood Flow Reserve","enrollment":80},{"nctId":"NCT01779869","phase":"PHASE4","title":"Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2013-01","conditions":"Ischemic Heart Disease","enrollment":16},{"nctId":"NCT01482169","phase":"NA","title":"Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)","status":"COMPLETED","sponsor":"Ochsner Health System","startDate":"2012-03","conditions":"Coronary Artery Disease","enrollment":48},{"nctId":"NCT03084562","phase":"","title":"Regadenoson vs Dipyridamole in Use as Pharmacological Stress Agent Before SPECT","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2017-05-03","conditions":"Myocardial Perfusion Imaging","enrollment":300},{"nctId":"NCT02092428","phase":"PHASE1","title":"Contrast- Enhanced Whole-Heart Coronary MRA at 3.0T (Tesla)","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2011-04","conditions":"Coronary Artery Disease","enrollment":333},{"nctId":"NCT01788631","phase":"PHASE2","title":"A Phase II Trial of Regadenoson in Sickle Cell Anemia","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-07","conditions":"Sickle Cell Anemia","enrollment":100},{"nctId":"NCT01710254","phase":"PHASE2","title":"Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients","status":"COMPLETED","sponsor":"University of Utah","startDate":"2013-01","conditions":"Atrial Fibrillation, Coronary Artery Disease","enrollment":30},{"nctId":"NCT01446094","phase":"PHASE4","title":"Diagnostic Study of Rapid Regadenoson Stress Cardiovascular Magnetic Resonance (CMR) to Detect Coronary Artery Disease","status":"UNKNOWN","sponsor":"Dipan Shah","startDate":"2011-08","conditions":"Coronary Artery Disease","enrollment":50},{"nctId":"NCT02597543","phase":"PHASE4","title":"Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction","status":"COMPLETED","sponsor":"Paul Kim","startDate":"2015-11","conditions":"Heart Transplant, Acute Graft Rejection, Chronic Graft Rejection","enrollment":14},{"nctId":"NCT01161121","phase":"PHASE1","title":"Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia","status":"COMPLETED","sponsor":"St. Louis University","startDate":"2010-07","conditions":"Coronary Artery Disease","enrollment":46},{"nctId":"NCT02628002","phase":"NA","title":"Anti-gravity Treadmill Exercise in Stress Myocardial Perfusion Imaging","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2015-12","conditions":"Coronary Artery Disease","enrollment":49},{"nctId":"NCT03090087","phase":"PHASE2","title":"The Effect of A2A Adrenoceptor Stimulation on the Diameter of Retinal Arterioles During Hypoxia in Vivo","status":"UNKNOWN","sponsor":"University of Aarhus","startDate":"2017-03-22","conditions":"Retinal Artery Occlusion","enrollment":20},{"nctId":"NCT00857792","phase":"NA","title":"Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2009-03","conditions":"Coronary Disease","enrollment":120},{"nctId":"NCT01618669","phase":"PHASE3","title":"A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2012-06","conditions":"Coronary Artery Disease (CAD)","enrollment":1147},{"nctId":"NCT01019486","phase":"PHASE4","title":"Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2009-11","conditions":"Coronary Artery Disease, Type 1 Diabetes Mellitus","enrollment":26},{"nctId":"NCT01150578","phase":"","title":"Evaluation of Myocardial Ischemia Using Standard Single Photon Emission Computed Tomography (SPECT) With Regadenoson and Simultaneous Cardiac Echocardiography","status":"UNKNOWN","sponsor":"Aiden Abidov","startDate":"2011-12","conditions":"Myocardial Ischemia","enrollment":380},{"nctId":"NCT01697995","phase":"","title":"Stress Induced Right Ventricular Uptake on Lexiscan Stress MPI","status":"UNKNOWN","sponsor":"Aiden Abidov","startDate":"2013-01","conditions":"Increased Right Ventricular Radiotracer Uptake","enrollment":650},{"nctId":"NCT01021865","phase":"","title":"Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2010-02","conditions":"Coronary Artery Disease, Diabetes Mellitus Type 2","enrollment":33},{"nctId":"NCT01840696","phase":"PHASE2","title":"Phase Analysis and Obstructive CAD on Rubidium PET","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2013-10","conditions":"Coronary Artery Disease","enrollment":""},{"nctId":"NCT01085201","phase":"PHASE1","title":"Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2010-04","conditions":"Sickle Cell Disease","enrollment":39},{"nctId":"NCT00907764","phase":"PHASE2","title":"Stress Echocardiography Study With Regadenoson","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2009-04","conditions":"Heart Disease, Coronary Artery Disease","enrollment":22},{"nctId":"NCT01809743","phase":"PHASE3","title":"Regadenoson and Adenosine","status":"COMPLETED","sponsor":"Lokien van Nunen","startDate":"2013-01","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT01370265","phase":"NA","title":"Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2011-02","conditions":"Coronary Artery Disease","enrollment":12},{"nctId":"NCT01918995","phase":"PHASE1","title":"Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2013-05","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT01778218","phase":"PHASE2","title":"A Single Center Study to Establish the Imaging Protocol of 99mTc-EC-DG in Evaluating the Presence and Severity of Coronary Artery Disease (CAD)","status":"COMPLETED","sponsor":"Cell>Point LLC","startDate":"2013-01","conditions":"Coronary Artery Disease","enrollment":2},{"nctId":"NCT01021618","phase":"NA","title":"Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging","status":"COMPLETED","sponsor":"Hartford Hospital","startDate":"2010-01","conditions":"Coronary Artery Disease, Myocardial Ischemia","enrollment":140},{"nctId":"NCT00862641","phase":"PHASE4","title":"A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-04","conditions":"Asthma, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive","enrollment":1009},{"nctId":"NCT00808314","phase":"PHASE4","title":"Lexiscan(TM) Rb-82 Myocardial Perfusion PET: A Comparison With Dipyridamole Stress","status":"UNKNOWN","sponsor":"Cardiovascular Imaging Technologies","startDate":"2008-12","conditions":"Coronary Artery Disease","enrollment":32},{"nctId":"NCT00863707","phase":"PHASE4","title":"A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-04","conditions":"Kidney Diseases, Coronary Artery Disease","enrollment":511},{"nctId":"NCT00881218","phase":"EARLY_PHASE1","title":"Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-06","conditions":"Ischemic Heart Disease","enrollment":50},{"nctId":"NCT00894179","phase":"","title":"Safety and Accuracy Study of Regadenoson Atropine Combination for Stress Echocardiography in Identification of Coronary Artery Disease","status":"UNKNOWN","sponsor":"Henry Ford Health System","startDate":"2009-05","conditions":"Coronary Artery Disease","enrollment":110},{"nctId":"NCT00797186","phase":"NA","title":"Less Invasive Detection and Treatment of Very Early Coronary Artery Disease in Patients With Diabetes Mellitus","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2008-11","conditions":"Type 2 Diabetes, Microvascular Dysfunction","enrollment":150},{"nctId":"NCT00859833","phase":"NA","title":"Effects of Body Mass Index on the Hyperemic Response to Regadenoson","status":"COMPLETED","sponsor":"University of Utah","startDate":"2009-02","conditions":"Obesity, Endothelial Dysfunction, Decreased Vascular Flow","enrollment":30},{"nctId":"NCT00208299","phase":"PHASE3","title":"ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2003-10","conditions":"Coronary Artery Disease","enrollment":1231},{"nctId":"NCT00208312","phase":"PHASE3","title":"ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2004-04","conditions":"Coronary Artery Disease","enrollment":787},{"nctId":"NCT00846079","phase":"PHASE3","title":"Myocardial Perfusion Assessment With Multidetector Computed Tomography","status":"UNKNOWN","sponsor":"Tennessee Heart and Vascular Institute, P.C.","startDate":"2009-02","conditions":"Coronary Artery Disease","enrollment":100}],"_emaApprovals":[],"_faersSignals":[{"count":61,"reaction":"NAUSEA"},{"count":58,"reaction":"HYPOTENSION"},{"count":53,"reaction":"DYSPNOEA"},{"count":35,"reaction":"CHEST PAIN"},{"count":35,"reaction":"DIZZINESS"},{"count":32,"reaction":"HEADACHE"},{"count":27,"reaction":"CARDIAC ARREST"},{"count":26,"reaction":"BRADYCARDIA"},{"count":26,"reaction":"VOMITING"},{"count":25,"reaction":"UNRESPONSIVE TO STIMULI"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"crossReferences":{"unii":"7AXV542LZ4","rxcui":"640062","splId":"4b43c865-fcdb-4e57-30a4-871e37e0e593","chemblId":"CHEMBL3989695","pubchemSID":"12015422"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"tmax":"1 to 4 minutes after injection","halfLife":"Initial phase: 2-4 minutes; Intermediate phase: 30 minutes; Terminal phase: approximately 2 hours","clearance":"Decreases with reduced creatinine clearance; increases with increased body weight; dose-independent within 0.3-20 µg/kg range","excretion":"Greater than 55% excreted unchanged in urine; dialyzable in vitro","metabolism":"Unknown in humans; incubation with rat, dog, and human liver microsomes as well as human hepatocytes produced [incomplete in source]","proteinBinding":"","bioavailability":"","volumeOfDistribution":"Similar across renal function groups; dose-independent within 0.3-20 µg/kg range"},"publicationCount":501,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturers":13,"_genericFilersChecked":true,"genericManufacturerList":["Accord Hlthcare","Apotex","Baxter Hlthcare Corp","Dr Reddys","Eugia Pharma","Ge Healthcare","Gland","Hikma","Hospira","Ims Ltd","Indies Pharma","Meitheal","Mylan"],"phase":"marketed","status":"approved","brandName":"Regadenoson","genericName":"Regadenoson","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"2022","enrichmentLevel":5,"visitCount":9,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-04-11T00:00:00.000Z","mah":"APOTEX","brand_name_local":null,"application_number":"ANDA207604"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-05-23T00:00:00.000Z","mah":"IMS LTD","brand_name_local":null,"application_number":"ANDA214252"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-07-12T00:00:00.000Z","mah":"GLAND","brand_name_local":null,"application_number":"ANDA207320"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-02-02T00:00:00.000Z","mah":"HIKMA","brand_name_local":null,"application_number":"ANDA215827"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-08-22T00:00:00.000Z","mah":"INDIES PHARMA","brand_name_local":null,"application_number":"ANDA218054"},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":"EMEA/H/C/001176"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rapiscan","application_number":null}],"trialStats":{"total":18,"withResults":10},"validation":{"fieldsValidated":6,"lastValidatedAt":"2026-04-20T08:37:06.840549+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}